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Introduction
INTRODUCTION
Diabetes  mellitus  is  a  syndrome  characterized  by  chronic  hyperglycemia  and 
disturbances in carbohydrate, protein and fat  metabolism associated with absolute or 
relative deficiencies in insulin secretion or it’s action. 
The metabolic dysregulation associated with diabetes mellitus causes secondary 
pathophysiological changes in multiple organ systems that impose a tremendous burden 
on the individual with diabetes. 
It’s deleterious effects on multiple organ systems like eye, renal system, heart and 
nervous  system  results  in  diabetic  retinopathy,  nephropathy  and  neuropathy  by 
microangiopathy. Being a microangiopathy affecting precapillary arterioles, capillaries 
and  venules,  it  presents  itself  either  as  non  proliferative  diabetic  retinopathy, 
maculopathy or proliferative diabetic retinopathy. The fact that the onset of moderate 
and severe visual loss resulting from diabetic retinopathy can be delayed and often kept 
controlled by good glycemic control, timely intervention in arresting the progression of 
retinopathy,  early  treatment  and regular  follow-up has  been extensively  studied  and 
documented.                                                                         
Effective control of risk factors including hyperglycemia, elevated blood pressure and 
hyperlipidemia delays progression of microangiopathy.
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Introduction  of  laser  in  ophthalmology  is  a  breakthrough  in  the  treatment  of 
severe nonproliferative and proliferative diabetic retinopathy. Laser photocoagulation is 
the  preferred  treatment  in  cases  of  severe  nonproliferative,  proliferative  diabetic 
retinopathy  and  clinically  significant  macular  edema.  Vitrectomy  can  be  done  for 
massive and recurrent vitreous haemorrhage and also for tractional retinal detachment.
Newer researches are being done on the usefulness of antivascular endothelial 
growth factor  in  the  treatment  of  diabetic  retinopathy.  It’s  efficacy  in  arresting  and 
reversing the disease process is under study.  
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R eview of Literature
HISTORY
1856 - Von Jager - first described diabetic retinopathy
1890 - Hirschberg - first classified & elaborated retinopathy
1943 - Ballantyne 
Lowenstein
-
1949 - Ashton -
clinical  and  histological  confirmation  of 
diabetic retinopathy
1949 - Gerd Meyer 
Schwickerath
- first recognised therapeutic effect of light 
on retina
1950 - Jonas Friedenwald - histopathological characterisation of DRJ1
1953 - Aarseth - hereditary factors in diabetic retinopathy
1962 - Patz, Moumenee - micro aneurysms in a diabetic dog
1965 - Engerman, 
Bloodworth Molitor
- retinal changes in dogs rendered diabetic
1966 - Gay, Rosenbaum - asymmetrical  retinopathy  in  carotid 
insufficiency  
1976 - Diabetic Retinopathy 
Study
- preliminary  report  on  effects  of 
photocoagulation therapy
1984 - Wisconsin 
Epidemiologic Study 
on Diabetic 
Retinopathy
-
prevalence of diabetic retinopathy
1985 - Early Treatment 
Diabetic Retinopathy 
Study
- effect  of  photocoagulation  on  diabetic 
macular edema
1985 - Diabetic Retinopathy 
Vitrectomy  Study  
- effect  of  early  vitrectomy  for  severe 
vitreous haemorrhage 
1988 - United Kingdom 
Prospective Diabetic 
Retinopathy Study
- effect of blood pressure and blood glucose 
on diabetic retinopathy
1993 - Diabetes Control & 
Complications Trial 
- effect  of  intensive  control  of  blood 
glucose on retinopathy
1998 - Klein - risk factors and progression of DR
2002 - Marbidis, Duker - intravitreal  triamcinolone  for  refractory 
diabetic macular edema.  
EPIDEMIOLOGY
Diabetes is  the most  prevalent  disease in middle  aged and elderly.   The Third 
National Health and Nutrition Examination Survey showed impaired fasting glucose and 
impaired  glucose  tolerance  in  9.7%  and  
15. 6% respectively in the 40 – 74 years age group.
Wisconsin  Epidemiologic  Study  on  Diabetic  Retinopathy (WESDR)  provides 
information  regarding  the  prevalence  and  risk  factors  associated  with  diabetic 
retinopathy.  It studied the disease among type I and type II diabetes. In younger onset 
group, which consists of patients whose age at diagnosis of diabetes was < 30 years, 
retinopathy was seen in 13% of patients with < 5 year duration of diabetes and it is 90% 
in 10- 15 years duration of diabetesS2.  PDR is present in 25% of patients with type I 
diabetes and 15 years duration.  
In older onset group, which consists of patients whose age at diagnosis of diabetes 
was ≥ 30 years of age and < 5 years of diabetes, 40% of those who take insulin and 24 of 
patients not on insulin have retinopathy.  PDR develops in 2% of patients with  type II 
diabetes and           < 5 years of diabetes and 25% in patients with ≥ 25 years of diabetes.
 The prevalence of diabetic macular edema is approximately                 18-20% in 
both Type I and Type II diabetesS2.
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RISK FACTORS 
 Level of glycemia
 Elevated serum lipids
 Blood pressure
 Duration of diabetes mellitus 
 Pregnancy
 Renal disease
 Coronary artery disease
Level of glycemia
Hyperglycemia is a strong factor in the development and progression of diabetic 
retinopathy. Benefits of better control continue to manifest even after nonproliferative 
and proliferative diabetic retinopathy has developed. Elevated glycosylated hemoglobin 
(HbA1c)  is  a  strong factor  for  the  progression  to  high  risk  PDRJ2,3.  There  is  a  35% 
decrease in the risk of retinopathy progression for every 10% reduction in the presenting 
HbA1c levelJ4.  The  higher  the  level  of  HbA1c  ,  the  higher  the  risk  of  developing 
complications related to diabetesJ5. 
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Serum lipids
Elevated levels of serum cholesterol is associated with increased severity of hard 
exudatesJ2,3,6. Elevated serum triglyceride levels are associated with an increased risk of 
developing high risk PDRS3,4 and decreased visual acuity. 
Blood Pressure
Intensive control of blood pressure slows down the progression of retinopathy and 
reduces the risk of other  microvascular  and macrovascular complications of diabetes 
mellitusS6J7.  Abnormal  systolic  and  diastolic  blood pressures  are  associated  with  the 
severity of retinopathy in both type I and type II disease. In type I, both are important 
and in type II, only systolic BP is related to the progression of the retinopathyS3.  
Duration of diabetes 
Duration of diabetes is a significant risk factor for the development of diabetic 
retinopathy S2,3,4. After 20 years of diabetes, all the type I and          > 60% of type II 
patients have some degree of retinopathy. 
When age at diagnosis is <30 yearsJ2 – 
<5 years of diabetes - retinopathy uncommon 
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<10 years of diabetes - 1.2% have PDR
>15 years of diabetes - 95%  have  some  degree  of 
retinopathy.
>35 years of diabetes - 67.2% have PDR
When age at diagnosis is >30J3 years – 
<5 years of diabetes - 40%  taking  insulin  have 
retinopathy
25% taking OHA have retinopathy 
2% have PDR
>15 years of diabetes - 84%  taking  insulin  have 
retinopathy.
53% taking OHA have retinopathy 
>25 years of diabetes - 25% have PDR
Pregnancy
Retinopathy is accelerated during pregnancy because of pregnancy itself  or  the 
changes in the metabolic controlJ8. 
Renal disease and Coronary artery disease
Both are associated with increased incidence of proliferative retinopathy. 
SEX INCIDENCE
Male sex is associated with more severe retinopathy.  The                    male : 
female ratio is 3:2J1,2. 7
GENETIC FACTORS
Relationship between HLA antigens expressed on the cell surface and the presence 
of retinopathy has already been documented. HLA – DR phenotypes 4/0, 3/0, and XX 
expressionS2,J9 is  associated  with  increased  proliferative  retinopathy.  Other  HLA 
phenotypes conferring such increased risk include HLA B8, HLA B15 and HLA DR4. 
OCULAR FACTORS
Myopia  reduces  the  prevalence  and  severity  of  diabetic  retinopathyJ9,10. 
Retinochoroidal scarring from trauma or inflammatory disease, reduces the prevalence 
of retinopathy by decreasing the retinal metabolism and thereby decreasing the need for 
oxygen and the release of vasoproliferative factors.   
PATHOGENESIS
There is a complicate interplay of various factors in the pathogenesis of diabetic 
retinopathyS5. 
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I. BIOCHEMICAL MECHANISMS 
1. Prolonged hyperglycemia 
It  is  the major etiologic agent  in the micro vascular  complications of diabetes 
mellitus. Three mechanisms seem plausible for diabetic retinopathy
i. Alteration in the expression of one or more genes resulting in increased amounts 
of altered gene products causing altered cell function.
ii. Non enzymatic glycation of proteins leading to cross linking and altered protein 
functionJ11. These products have very long cellular lifetime.
iii. Chronic hyperglycemia causes accelerated oxidative stress  in cells resulting in 
toxic  end productsJ12.  Also  increased  activity  of  polyol  pathway  increases  the 
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NADH/NAD+ ratio  resulting in  increased  toxic  end product,  by  a  mechanism 
called hyperglycemic pseudo hypoxiaJ13.
2. Sorbitol Pathway
Aldose  sugars  are  converted to  their  respective  alcohol  by  the  enzyme aldose 
reductase and again to their key to sugars by dehydrogenaseS5.  
Glucose is a relatively poor substrate for aldose reductase with high Km (binding 
constant). Under normal conditions, glucose is acted on by hexokinase to proceed on the 
glycolytic cycle.
In  uncontrolled  hyperglycemia,  the  hexokinase  pathway  gets  saturated  and 
glucose  is  acted  upon  by  aldose  reductase  using  NADP  as  cofactor,  resulting  in 
formation of excess sorbitol.
Further oxidation of sorbitol to fructose is a slow process resulting in building up 
of intracellular sorbitol leading on to cell damage and microvascular complicationsJ14.
Glucose
Sorbitol
Fructose
NADP
NADPH
Slow 
Process Oxidation
Increased 
accumulation of 
Sorbitol
Cell 
Injury
Aldose 
Reductase
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3. Diacyl glycerol and protein kinase C
Hyperglycemia  causes  an  increase  in  diacyl  glycerol  which  inturn  activates 
protein kinase C which causes alteration in expression of type IV collagen and extra 
cellular matrix proteins of endothelial cellsJ15.
4. Vascular endothelial growth factor (VEGF)
VEGF is  associated  with  proliferative  retinopathy and maculopathy.   Hypoxia 
stimulates the release of VEGF from the retinal and optic nerve glial cells of diabeticsJ16.
II. RHEOLOGICAL MECHANISMS
1. Abnormality of Platelets
Increased platelet adhesion, increased aggregation, increased factor VIII – Von 
Willebrand factor  and decreased  lifespan of  platelets  also  play  a  role  in  retinopathy 
developmentS10.
2. Abnormalities of Red Blood Corpuscles (RBC)
In  diabetic  individuals,  there  is  increased  rouleaux  formation  and  reduced 
deformability  of  RBC.  This  is  presumed  to  be  due  to  altered  α2 macroglobulin, 
haptoglobulin and increased fibrinogen.  
11
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PATHOLOGY
1. Capillary basement membrane thickening 
Quantitative electron microscopic  immunocytochemical  studies  show increased 
thickening of  capillary  basement  membrane  with  an increase  in  type  IV collagenJ17. 
Studies  show  along  with  thickened  basement  membrane,  there  is  Swiss  Cheese 
vacuolisation and fibrillar  collagen deposition.  Certain functions served by basement 
membrane are deranged in diabetesS2. They are
 Structural rigidity to blood vessels
 Filtration barrier  for various molecules 
 Barrier to vasoproliferation
2. Loss of microvascular intramural pericytes
The  capillary  wall  has  pericytes  surrounding  the  endothelial  cells.  Of  these, 
pericytes have aldose reductase rather than endothelial cells. Hence more sorbitol gests 
accumulated  in  pericytes  causing  damage  to  them.  The  drop  out  of  pericytes  is 
recognized as empty, balloon–like space bulging from the capillary wallJ18,19.  Normal 
pericyte to endothelial cell ratio is 1:1. In diabetic retinopathy this ratio gets alteredS7. 
3. Microaneurysms 13
On  trypsin  digested  retinal  mounts,  microaneurysms   appear  as  hypercellular 
saccular  outpouchings  of  capillary  wallJ19,20.  Microaneuryms  may  hyalinize  and  get 
occluded with PAS-positive material.
4. Capillary acellularity 
Complete loss of all cellular elements from retinal microvessels. 
5. Breakdown of blood-retinal barrier 
Breakdown of blood-retinal barrier occurs due to
 Opening of tight junctions (Zonulae occludentes) between adjacent microvascular 
endothelial processesJ20.
 Fenestration of endothelial cell cytoplasm.
 Increase in transport by endocytic vesicles. 
6. Exudates 
Hard exudates : Hard,  yellow,  waxy  lesions 14
consisting  of  lipid  and proteinaceous  material  in  Henle's 
layer. 
Cotton wool exudates : Clusters of ganglion cell axons in 
the nerve fiber layer with bullous dilatation (cytoid bodies) 
at the site of ischaemiaS7. 
7. Neovascularisation 
                      The growth of new vessels in retina either on disc or elsewhere. 
Stage 1  : The stage of naked vessels.
Fine, new vessels without supporting connective tissue arising 
from capillaries, grows in the plane of retina or invades vitreous. 
Stage 2 : The stage of condensation of connective tissue   
There is laying of connective tissue around the naked vessels 
which starts condensing.
Stage 3 : The stage of cicatrisation 
Gradual  reduction  in  number  and  size  of  new  vessels  is 
associated  with  an  increase  in  the  connective  tissue  density.  This  on 
contraction forms sheets and bandsS1. 
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CLASSIFICATION
Diabetic retinopathy is classified by Hirschberg as early as 1890. Later it  was 
further classified by Ballantyne and Michaelson (1947 – 1962), Scott (1951), Alaerts 
and Slosse (1957) and Lee (1966).                  Duke Elder classified diabetic retinopathy 
as 
a) Pre-retinopathy Stage
Decreased activity in ERG and EOG
b) Simple Diabetic Retinopathy
Appearance of microaneurysms, superficial and deep retinal haemorrhages, hard 
and soft exudates and vascular anomalies.
c) Proliferative Stage
Neovascularisation  over  the  disc  or  elsewhere,  vitreous  haemorrhage  and 
complications like retinal detachment.
Early treatment diabetic retinopathy study (ETDRS) classifiesS4 nonproliferative diabetic 
retinopathy (NPDR) as follows
 Mild : atleast one microaneurysm, microaneurysms or haemorrhages 
< standard photograph 2A
 Moderate : microaneurysms &  haemorrhages  > standard  photograph 
2A,   soft  exudates,  venous  beading  and  intraretinal  microvascular  anomalies 
(IRMA) 
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 Severe : any one of the following
(4:2:1 rule) microaneurysms / haemorrhages 
in 4 quadrants or venous beading in >2 quadrants or IRMA 
in one quadrant.
 Very severe : any two or more of the above mentioned J21.  
ETDRS classifies clinically significant macular edema as
1. Thickening of retina at / within 500 µ from center of the macula or 
2. Hard exudates at / within 500µ from center of the macula with adjacent retinal 
thickening or 
3. zone of retinal thickening of one disc area or larger, a part of it is within, one disc 
diameter of the center of maculaJ22 
Diabetic Retinopathy Study classifies proliferative diabetic retinopathy (PDR) as
 Early : New vessels on the disc / elsewhere 
 High risk : New vessels over disc >1/3–1/4 disc area or 
New  vessels  over  disc  and  preretinal  or  vitreous 
haemorrhage or 
New  vessels  elsewhere  >1/2  disc  area  and  preretinal  or 
vitreous haemorrhage.
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STUDIES ON DIABETIC RETINOPATHY
Early treatment diabetic retinopathy study (ETDRS) 
This  is  a  randomised  clinical  trial  to  ascertain  the  effect  of  laser  in  diabetic 
retinopathy. 
Results :
 Aspirin  did  not  alter  the  progression  of  diabetic  retinopathy  or  increase  vitreous 
haemorrhage.
 Early PRP is not indicated in eyes with mild - moderate retinopathy.  
 Early PRP resulted in reduction in the risk of severe visual loss.
 Focal  photocoagulation for  diabetic  macular  edema reduced the risk  of  moderate 
visual loss and increased moderate visual gain.
Diabetic Retinopathy Study (DRS)
This clinical trial evaluated the effect of PRP in diabetic retinopathy. Results :
 Xenon arc photocoagulation caused a  > 50% reduction in the rates of severe visual 
loss (SVL). 
 Treated eyes with high risk PDR achieved the greatest benefit.
United Kingdom Prospected Diabetic retinopathy Study(UKPDS)
This  is  a  randomised  control  trial  which  was  conducted  to  evaluate  the 
effectiveness of intense control of blood pressure and blood glucose in type II diabetic 
patients.
Results :
18
Intense control of blood pressure and blood glucose slowed the progression of 
retinopathy and reduced the risk of microvascular complications. 
Diabetes Control and Complications Trial (DCCT)
This study was conducted with the aim to evaluate the effectiveness of intense 
control of blood glucose in type I diabetes.
Results :
 Intensive control of blood glucose reduced the risk of developing retinopathy by 76% 
and slowed the progression by 54%.
 It reduced the risk of neuropathy by 60% and nephropathy by 54%. 
Diabetic Retinopathy Vitrectomy Study (DRVS)
This randomised prospective clinical trail investigated the role of vitrectomy in 
diabetic retinopathy.
Results :
Early vitrectomy in type I diabetics had clear benefit  over deferral group, especially 
severe PDR benefited more.
Wisconsin Epidemiologic Study on Diabetic Retinopathy (WESDR)
This  study  depicted  the  prevalence  and  risk  factors  associated  with  diabetic 
retinopathy.
19
CLINICAL FEATURES
I. NON PROLIFERATIVE DIABETIC RETINOPATHY
The pathological processes in NPDR include retinal capillary micro aneurysm, 
increased vascular permeability and eventual capillary closure.
1. Microaneurysm 
Meckanzie and Nettleship were the first to note microaneurysms.They appear as 
deep red dots varying from 15µm to 60 µm in diameter. It is most common in posterior 
pole and appears & disappears with time. 
Weakness  of  capillary  wall,  loss  of  pericytes,  release  of  vasoproliferative  factor, 
abnormalities of adjacent retina and increased intra luminal pressure J18 play a role in its 
development. 
 
2. Hard exudates 
With progressing retinopathy, vascular permeability of retinal capillaries increases 
resulting  in  leakage  of  serum  and  lipids  resulting  in  hard  exudates  and  macular 
edema.Hard exudates are yellow - white intra retinal lipid deposits located at the border 
of edematous and nonedematous retina. They present as clusters, plaque and cricinate / 
ring patterns.
            MILD NPDR        MODERATE NPDR
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          SEVERE NPDR     VERY SEVERE NPDR
       VENOUS LOOPING        PDR
        ADVANCED PDR  
MACULOPATHY
3. Intra retinal haemorrhages 
Superficial  haemorrhages  :  Flame  shaped  due  to  the  accumulation  of  blood  in  the 
superficial retinal layers parallel to the coursing nerve fibersS6. 
Deep haemorrhages : Dot and blot in the inner nuclear and outer plexiform layers and its 
breaks through the confines of Muller cell processes. 
4. Capillary closure 
Capillary closure results in patchy areas of nonpurfused retina with clusters of 
microaneurysms, cotton wool spots, IRMA, haemorrhages and venous beading. 
Cotton wool spots : White patches with fraying borders merging into the retina, present 
in areas of microvascular occlusion and  nonperfusion.
IRMA : Intra retinal vascular shunts and they do not leak on fluorescein angiography. 
II. MACULOPATHY 
It is one of the major causes of visual loss in diabetic retinopathyS2. It is more 
commonly associated with NIDDM and older patients. Maculopathy presents either as 
macular edema or macular ischaemiaS4. Macular edema can present as focal or diffuse 
edema which may be clinically significant.
Focal macular edema : 
 areas of leakage from micro aneurysm and IRMA. 
 associated with rings of hard exudates and microaneurysmsS4,J3. 
Diffuse macular edema : 
 has diffuse retinal thickening 
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 wide spread retinal  capillary abnormality  with diffuse leakage dueto extensive 
breakdown of blood retinal barrier.
 associated often with cystoid macular edema.
Macular Ischaemia :
 capillary nonperfusion 
 microaneurysm clusters at the margins of nonperfusion
 more visual loss with clinically normal appearing macula
 enlargement of foveal avascular zoneJ2 
 if >1000 µm in diameter, severe visual loss ensues.  
Clinically significant macular edema (CSME) :
The  CSME  was  defined  by  ETDRS  which  helps  in  its  management.  10%  of 
diabetics have macular edema and in 40% of these, the center of the macular is involved 
and have significant visual lossJ23. 
II. PROLIFERATIVE DIABETIC RETINOPATHY (PDR)
The appearance of new vessels over disc or elsewhere in the retina is considered 
as PDR. The most  plausible explanation for endothelial  proliferation is ischaemia of 
inner retinal layers secondary to closure of parts of retinal capillary bed J24,25,26. Based on 
the location the new vessels can be grouped as 
 New vessels involving the retina but sparing the disc
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 New vessels involving the disc
 New vessels in the anterior chamber angle 
New vessels are seen commonly within 45 degrees of optic               disc S4,J27,28. 
45% have new vessels outside the optic zone alone and 45% have new vessels both in 
the optic zone and outside itJ30.
STAGES OF PDR
Stage of proliferation
 Fine new vessels at the disc margin of size one eighth to one fourth that of major 
retinal vein.
 New vessels  more  frequently  occur  along  superotemporal  vein  J27,28 and  grow 
along retinal plane or invade vitreous either radially or irregularly.
 Deposition of fibrous tissue around blood vessels.
Stage of regression
Decrease in the caliber and the number of vessels occurs and it is followed by 
replacement of them with fibrous tissue J29,30.
PDR can be classified as early PDR, high risk PDR and advanced stage, where 
there  is  extensive  vitreous  haemorrhage  precluding  grading,  retinal  detachment 
involving  macula  or  phthisis  bulbi  or  enucleation  secondary  to  a  complication  of 
diabetic retinopathy.
22
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SEQUELAE
1.Contraction of vitreous
 Thickened posterior vitreous adjacent to the site of new vessels with fibrous tissue 
along its posterior surface.
 Vitreous contraction with the vector pulling the posterior vitreous forward.  
 Eventual posterior vitreous detachment commonly occurs along superotemporal 
vessels,  temporal  to  macula  and  above/below  the  disc.  The  traction  on  new 
vessels can lead to vitreous haemorrhage.
2. Tractional   retinal detachment
The occurrence and severity of retinal detachment is influenced by the timing and 
degree  of  vitreous  shrinkage  and  vitroretinal  adhesions.  With  contraction  of 
fibrovascular  proliferation,  distortion  and  displacement  of  macula  occurs.  Macula  is 
usually dragged nasally and verticallyJ31.
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3. Involutional diabetic retinopathy 
With  complete  vitreous  contraction  and  detachment,  marked  reduction  in  the 
caliber of retinal vessels is characteristic. There is severe retinal ischaemia, resulting in 
marked visual loss J32,33.
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CLINICAL EVALUATION
Visual Acuity
The  evaluation  of  retinopathy  patients  starts  with  assessing  visual  acuity. 
Refraction is to be done in all cases of diabetic retinopathy and best corrected visual 
acuity must be documented.
Colour vision
In diabetes,  the sensitivity  of blue cones is  depressed and the common defect 
observed is in the blue-yellow range. It is best detected by fransworth munsell hundred 
hue test.
Fields
Examination of fields by perimetry shows areas of scotoma which represent the 
corresponding abnormal areas of retina.
Intraocular pressure
IOP is  measured in diabetics  to rule out neovascular glaucoma.  
Ophthalmoscopy
By direct  ophthalmoscopy,  detailed  fundus  examination  is  carried  out.   Even 
though the area visualized is smaller, it provides a good magnification for the details to 
26
be seen clearly.  Indirect Ophthalmoscopy is carried out to visualize the entire retina 
including peripheral retina. 
Slit Lamp Examination 
Using slit lamp biomicroscope, the retinal examination and angle study are done 
with Goldmann 3 mirror lens, +78D and 90D lens.
Macular Function Tests 
The  assessment  of  macula  is  recommended  in  all  cases  of  maculopathy.  The 
following tests can be performed.
 2 point discrimination 
 Photo stress Test
 Amsler grid test
 Blue field entoptoscope
Flourescein angiography
Indications in diabetic retinopathy
 to define the focal and diffuse leaks in diabetic maculopathy
 to delineate the extent of ischaemic zone in maculopathy
 to  locate areas  of  capillary  nonperfusion  and  leakage  from  new  vessels  in 
proliferative stage
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 to identify the persistence, progression or resolution of macular edema following 
laser photocoagulation.
 to detect small microaneurysms <20 microns 
The property of fluorescein to absorb higher energy, shorter wavelength blue light 
and to emit lesser energy, longer wavelength, green light, with this change occurring 
over  a  brief  period  of  time  (<10-8)  is  called  fluorescence.  This  property  is  used  in 
fluorescein angiographyS8.
Features
Microaneurysms           : well  defined 
hyperfluorescence against dark    choroidal background 
J34.
Retinal haemorrhages   : well  defined  areas  of 
hypoflourscence.
                   Superficial : blocked  retinal  &  choroidal 
fluorescence.
                    Deep         : blocked  choroidal 
fluorescence alone
Hard exudates               : areas of blocked fluorescence
Cotton wool spots         : areas of blocked fluorescence.
Capillary nonperfusion : well  defined  areas  of 
hypofluorescence between retinal vessels.
                                        non visibility of capillaries.
NVD/NVE                    : increasing  intense 
hyperfluorescence due to leakage J35. 
Focal macular edema    : focal  leaks  from 
microaneurysms  with  blocked  fluorescence  from  hard 
exudates and haemorrhages.
Diffuse  macular edema : dilatation  of  capillaries  and 
diffuse  leaks  in  early  venous  phase.  Floral  pattern  in 
cystoid macular edema.
Ischaemic maculopathy : enlarged and irregular  foveal 
avascular zone J36, capillary dropouts in perifoveal area. 
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MANAGEMENT
EVALUATION BIOCHEMICAL PARAMETERS 
Estimation of Fasting Blood Glucose 
This is done by ortho-toludine method. 
Glycosylated hemoglobin (HbA1c)
Estimation of HbA1c is done using high pressure liquid chromatography.
Principle :
This coloured compound is then measured.
Total Cholesterol (Modified Salkowski's Method– Wybenga Method)
   H-C =O
  H -C-OH
HO-C-H
   H-C-OH
  H-C-OH
      CH2OH
glucose
+ βA-NH2
Valine of 
β Chain (Hb)
ä
   H-C =N-βA
  H -C-OH
HO-C-H
   H-C-OH
  H-C-OH
      CH2OH
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 →
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ketamine 
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Phosphoric acid
Heating
Thiobarbituric 
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The principle of this reaction is that cholesterol reacts with ferric chloride ions in 
acetic acid followed by sulphuric acid. This method is modified by Wybenga and this is 
used to estimate total cholesterol.
HDL Cholesterol (Loper and Virella)
In  this  procedure,  the  VLDL,  chylomicrons  and  LDL  are  separated  by 
phosphotungstate in the presence of Mg+ ions and HDL cholesterol is estimated from the 
supernatant. 
Triglycerides (Foster and Dunn) Hantzsch Reaction
Triglycerides are extracted by heptane isopropanol from phospholipids and are 
saponified by potassium hydroxide. The liberated glycerol is oxidised to formaldehyde 
which  then  combines  with  acetyl  acetone  and  ammonia  to  give  a  dihydrobutidine 
derivative. It is then measured. 
31
TREATMENT 
The treatment depends on the type and severity of retinopathy.
NONPROLIFERATIVE RETINOPATHY
For  mild  and moderate  NPDR,  strict  adherence to  normal  levels  of  glycemia, 
blood  pressure  and  lipid  status  is  the  mainstay  of  effective  treatment.  Scatter  laser 
photocoagulation is generally not recommendedS4. 
The Early Treatment Diabetic Retinopathy Study and the Diabetic Retinopathy 
Study  recommend  photocoagulation  as  the  treatment  of  choice  for  severe  and 
progressive form of retinopathy and clinically significant macular edema.
Severe NPDR
     For severe NPDR, scatter laser treatment is appropriate when
 Disease process is progressing rapidly
 Close follow-up unlikely.
Macular edema
ETDRS demonstrated that retinal laser therapy applied to macula reduces the risk 
of substantial worsening of vision by 50%.  
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Focal macular edema :
Direct laser using green or yellow wavelength applied over microaneurysms that 
are between 500-3000µm from the center of the maculaS9. Parameters for focal treatment
Spot size    : 50-100µm
Duration     : ≤0.1s
Power        : sufficient to cause 
blanching of microaneurysm / RPE
Diffuse macular edema  :
A light intensity grid pattern using green or yellow wavelength to all  areas of 
diffuse  leakage  >500µm from the  center  of  macula  and  500µm from the  temporal 
margin of the optic disc. Parameters for grid pattern.
Spot size    : 50-100µm
Duration     : ≤0.1s
Power        : sufficient to cause  blanching of RPE
Spots are placed at least one burn width apart.  CSME is more benefited from 
laser.
Ischaemic maculopathy : 
As the macula has capillary non perfusion, focal or grid laser is not recommended.
PROLIFERATIVE DIABETIC RETINOPATHY
Medical management:
The principal goal is controlling both systemic and local factors that influence the 33
progression  from  NPDR  to  PDR.  This  includes  good  glycemic  control,  control  of 
hypertension, renal disease and coronary artery disease.
       DCCT and UKPDS have documented that intensive glycemic control is associated 
with  a  reduced  risk  of  newly  diagnosed  retinopathy  and  a  reduced  progression  of 
existing retinopathy.
Panretinal photocoagulation (PRP) :
PRP  is  done  to  cause  regression  of  existing  new  vessels  to  prevent  progressive 
neovascularisationS11.
ETDRS and DRS study model, the parameters are
Number of burns    : ≥1200
Spot size                  : 500µm
Duration                  : 0.1.
Spots are placed at least ½ burn width apart and the number of sessions are more 
than two. The rate of severe visual loss is reduced from 16% in untreated eyes over two 
years to 6% in treated eyes, documenting a reduction of 57%J37.
Surgical management
Surgical intervention is the mainstay of contemporary management for vitreous 
haemorrhage and tractional retinal  detachmentJ38.Type I patients with severe vitreous 
haemorrhage show an advantage due to early vitrectomyJ39. 
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Indications for pars plana vitrectomy :
 Dense non clearing vitreous haemorrhage
 Tractional retinal detachment threatening macula
 Combined tractional and rhegamatogenous  detachment
 Diffuse macular edema with post hyaloid traction
 recurrent vitreous haemorrhage
Recent Advances 
In patients with refractory CSME, intravitreal administration of corticosteroids 
showed to be useful. Currently, several drug delivery modalities are in clinical trials to 
investigate their efficacy. 
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ETDRS RECOMMENDED OCULAR EXAMINATION SCHEDULES6
Age at onset Time recommended
Routine minimal follow 
up(in the absence of 
retinopathy)
≤30 years 5 years of diabetes yearly
>30years At the time of diagnosis yearly
Pregnancy Before conception/first 
trimester
3 monthly
RECOMMENDED FOLLOW-UP SCHEDULE IN DIABETIC RETINOPATHY 
PATIENTS
Retinal Abnormality Suggested Follow-up
Normal or rare micro aneurysms Annually
Mild NPDR Every 9 months
Moderate NPDR Every 6 months
Severe NPDR Every 4 months
CSME Every 2-4 months 
PDR Every 2-3 months 
LEVELS OF PRVEVENTION OF DIABETIC RETINOPATHY
The visual loss due to diabetes can be prevented by intervening at various stages 
of the diseases.
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Primary prevention
     Once the diagnosis of diabetes is made, strict control of glycemic status by diet, 
exercise and drugs .Periodic ophthalmic examination must be carried out. Referral of the 
diabetic  individuals  to  ophthalmologists  regularly  or  as  soon  as  signs  of  micro 
angiopathy like microalbuminuria sets in.
Secondary prevention
Blindness can  be prevented  in  NPDR patients  by  the modification of  the risk 
factors. Fluorescein angiography is done to find out the type of maculopathy at initial 
stages. Laser photocoagulation is given for maculopathy and PDR to prevent visual loss.
Tertiary prevention
When the patient is in advanced proliferative stage, relevant surgical treatment 
given. Further visual rehabilitation is given by low vision aids.
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Aim of the Study
AIM OF THE STUDY
1. To study the magnitude of diabetic retinopathy in diabetic individuals with relation 
to age and sex of the individual and duration of diabetes. 
2. To assess the possible risk factors associated with diabetic retinopathy.
3. To assess the associated systemic disorders in diabetic retinopathy.
4. To assess the relationship of the biochemical parameters like baseline lipid, fasting 
blood glucose and HbA1c to diabetic retinopathy.  
5. To assess the incidence of maculopathy in diabetic retinopathy. 
6. To assess the benefits of laser in diabetic retinopathy.
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Materials and Methods
MATERIALS AND METHODS
The  diabetic  individuals  reporting  or  being  referred  to  Coimbatore  Medical 
College Hospital, Eye Department during the period of January 2006 to October 2007 
were taken into the study.
This included both type I and type II diabetic individuals of either sex. Pregnant 
women and children were excluded from the study. A total of 90 visually symptomatic 
diabetic patients with retinopathy were evaluated. 
A careful history of the patients regarding their age and sex, duration of diabetes 
mellitus,  risk  factors,  associated  systemic  disorders  like  nephropathy,  hypertension, 
coronary  artery  disease  (CAD)  and  neuropathy  was  recorded.  The  nature  of  the 
treatment of diabetes was noted.
Materials used 
1. Snellen's  visual acuity chart 
2. Schiotz tonometer
3. Haag Streit / Carl Zeiss slit lamp
4. Direct ophthalmoscope 
5. Indirect ophthalmoscope 
6. Goldmann three mirror, +78D and 90D lens
7. Topcon fundus camera 
The  following  investigations  were  done  to  evaluate  the  risk  factors  and  systemic 
disorders which are associated with diabetic retinopathy39
1. Fasting blood sugar (Orthotoludine method)
2. Glycosylated hemoglobin (high pressure liquid chromatography)
3. Total cholesterol (modified Salkowski – Wybenga Method)
4. HDL (Loper and Virella)
5. TGL (Foster – Dunn, Hantzsch Reaction)
6. LDL(enzymatic method)
7. Blood Urea (urease method)
8. Serum creatinine (Jasse kinetic method)
9. Urine – albumin, sugar
Blood Pressure was measured and CAD was diagnosed based on the history of 
documented  myocardial  infarction  and  drug  treatment  for  CAD.  Neuropathy  was 
diagnosed based on the history and its treatment. 
Methods
Work up started with testing the unaided visual  acuity  of  each eye separately 
using  Snellen's  chart.  Using  slit  lamp  biomicroscopy,  the  anterior  segment  was 
evaluated. Intraocular pressure measured using Schiotz tonometer. Pupils were dilated 
with tropicamide eye drops and retinoscopy and refraction done.  The best  corrected 
visual  acuity  was  noted.  The  retinal  examination  was  done  with  direct  and indirect 
ophthalmoscopes,  +78D and  Goldmann  three  mirror  lens.  Fundus  photograph  taken 
using Topcon fundus camera. Fluorescein angiography was done with special emphasis 
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to 
 Leaking micro aneurysms and their location
 Leaking new vessels
 Focal and diffuse leaks in macula
 Presence of ischaemia in macula
Criteria for Photocoagulation
1. Focal Photocoagulation
 For patients with focal leaks especially in parafoveal and perifoveal areas. 
 Done with argongreel laser of 50-100µ spot size for   0.05-0.1s.
2. Grid Photocoagulation
 For patients with diffuse exudation and clinically significant macular edema. 
 100µ spot closed to fovea and 200µ spot away from fovea with moderate intensity. 
3. Panretinal (scatter) Photocoagulation  
 For eyes with rapidly progressing severe NPDR, proliferative retinopathy with well 
established revascularization over disc / elsewhere.
 Very severe NPDR with poor compliance. 
 1200 – 1600 burns of size upto 500µ given, occupying the posterior pole sparing 
macula.
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 For combined maculopathy with diabetic retinopathy that is approaching high risk 
PDR, a prior focal photocoagulation for edema given followed by PRP. 
 Blood pressure was recorded in sitting posture. Fasting blood sugar, glycosylated 
hemoglobin, lipid profile, blood urea, serum creatinine and urine routine done. 
Follow up 
Patients are followed up every two months with special emphasis laid on fundus 
evaluation for regression existing new vessels, appearance of new vessels, decrease in 
retinal haemorrhage and exudates and detect early iris neovascularisation by slit lamp 
examination. 
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Observation 
OBSERVATION
In  our  study  conducted  from  January  2006  to  October  2007,  270  diabetic 
individuals reported to eye department, out of which 90 visually symptomatic diabetics 
with  retinopathy  of  varying  severity  were  taken  into  study.  In  the  evaluation  of 
biochemical  parameters  the  values  above  the  following  levels  are  considered  as 
abnormalS12,J40. 
 Fasting blood glucose = 126mg / dl
 HbA1c = 6%
 Total cholesterol = 200mg / dl
 LDL cholesterol = 100mg / dl
 HDL cholesterol <40mg / dl
  Triglycerides = 160mg / dl
 Blood urea = 40 mg / dl
 Serum creatinine >1.5 mg / dl
 Blood pressure = 140/90mmHg
Statistical Tools
The parameters under study were compared by applying Z test i.e., test based on 
normal distribution, since the sample size was large (n>30). The results were obtained 
using  SPPS  11  version  package.  The  data  collected  were  analysed  on  the  basis  of 
descriptive statistics, mean and standard deviation. The graphs and diagrams were also 
used to represent the data. Microsoft word and excel had been used to generate graphs 
and tables. 
Table – 1 : Age Distribution 
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Age Group Number (n) Percentage (%)
31-40 3 3.33
41-50 20 22.22
51-60 42 46.67
61-70 21 23.33
71-80 4 4.45
Figure showing the percentage of Age Distribution
In  our  study,  the  predominant  age  group  affected  is  51-60  years  (46.67%) 
followed by 61-70 years (23.33%) least  involved group is less than 40 years.  In the 
study  conducted  by  Khandekar  et  al.,  2003J41showed  that  the  retinopathy  rate  was 
common in 50-59 years followed by 60-69 years. 
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Table – 2 : Gender Distribution 
Gender Number (n) Percentage (%)
Males 56 62.22
Females 34 37.78
Figure showing the percentage of Gender Distribution  
In our study, diabetic retinopathy was prevalent more in males(62.22%). The sex 
ratio between males and females was 1.6 :  1.  This is  comparable to Bodansky et al 
1982J44, which showed a sex ratio between males and females as 2:1.
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Table – 3 : Age - Gender Distribution 
Age Group
Number (n) Percentage (%)
Males Females Males Females
31-40 2 1 2.22 1.11
41-50 13 7 14.44 7.78
51-60 26 16 28.89 17.78
61-70 11 10 12.22 11.11
71-80 4 - 4.45 -
Figure showing the percentage of Age - Gender Distribution  
In both males and females predominant involved is 51-60 years (28.89% of males 
and 17.78% of females). In males the next common age group involved is 41-50 years 
(14.44%), whereas in females it is between 61-70 years (11.11%). 
Table – 4 : Family history of diabetes  
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Family History Number (n) Percentage (%)
Present 41 45.56
Absent 49 54.44
Figure  showing the percentage of Family history of diabetes  
In our study, most of the patients (54.44%) did not show positive family history 
whereas 45.56% of diabetics had family history of diabetes.  Out of the 41 diabetics 
having positive family history, 16 (39%) had nonproliferative diabetic retinopathy and 
25 (61%) had proliferative retinopathy. 
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`Table – 5 : Distribution of Diabetic Retinopathy  
Retinopathy
Number
(n=270)
Percentage
(%)
Present 90 33.33
Absent 180 66.67
Figure showing the percentage of Distribution of Diabetic Retinopathy  
Out of  the 270 diabetic  patients  reported to  our  department,  90 (33.33%) had 
diabetic retinopathy of varying severity. 180 (66.67%) did not show any evidence of 
diabetic retinopathy. It can be compared to the study conducted by Agrawal et al, 2003J43 
which showed 28.9%  retinopathy.
Table – 6 : Severity of Diabetic Retinopathy  
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Severity Number (n=90)
Percentage 
(%)
Total
n %
NPDR
Mild 10 11.11
Moderate 27 30
Severe 15 16.67
Very severe 6 6.67
58 64.44
PDR
Non-HRC 9 10
HRC 21 23.33
Advanced 2 2.22
32 35.56
Figure showing the severity of Diabetic Retinopathy  
In  a  total  of  90  patients  with  diabetic  retinopathy,  58  (64.44%)  had 
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nonproliferative  retinopathy  and  32  (35.56%)  had  proliferative  retinopathy.  Of  the 
NPDR, the prevalence of mild, moderate, severe and very severe retinopathy is 11.11%, 
30%, 16.67% and 6.67% respectively. Among 32 PDR patients, 21 (23.33%) presented 
with  high  risk  characteristics,  whereas  9  (10%)  presented  with  non  high  risk 
characteristics. 2 patients (2.22%) were in advanced stage. 
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Table – 7 : Incidence of Maculopathy  
Maculopathy 
Status
Number
(n=270) 
Percentage 
(%)
Total
n %
Maculopathy
With NPDR 19 7.04
With PDR 7 2.59
26 9.63
No Maculopathy 244 90.37 244 90.37
Figure showing the percentage of Incidence of Maculopathy  
In our study, 26 (9.63%) individuals had maculopathy. This correlated with the 
study conducted by Khandekar et al 2003J41. It was associated more with NPDR in 19 
individuals (7.04%) then with PDR (2.59%). 
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Table – 8 : Duration of Diabetes   
Duration  
(in years)
Number
(n=90)
Percentage
(%)
< 5 20 22.22
6-10 30 33.33
11-15 29 32.22
16-20 9 10.00
21-25 2 2.22
Figure showing the percentage of Duration of Diabetes   
In less than 5 years duration of diabetes, only 20 (22.22%) had retinopathy. Of 90 
individuals with retinopathy, almost one third (33.33%) presented with retinopathy in 
6-10 years of diabetes. This is closely followed by 29 individuals  (32.32%) presenting 
with retinopathy in 11-15 years of diabetes. 
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Table – 9 : Duration of diabetes  and severity of retinopathy
Severity
Duration in years
<5 6-10 11-15 16-20 21-25
Mild  
n=10 (%)
9 (10%) 1 (1.1%) - - -
Moderate  
n=27 (%)
7 (7.8%) 14 (15.6%) 5 (5.6%) 1 (1.1%) -
Severe  
n=15 (%)
2 (2.2%) 3 (3.3%) 9 (10%) - 1 (1.1%)
Very Severe 
n=6 (%) - 3 (3.3%) - 2 (2.2%) 1 (1.1%)
PDR  
n=32 (%)
2 (2.2%) 9 (10%) 15 (16.7%) 6 (6.7%) -
Figure showing the percentage of Duration of diabetes  and severity of 
retinopathy
As the duration of diabetes increased, the severity of retinopathy also increased. 
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At  less  than  5  years  of  diabetes,  nonproliferative  changes  predominate  (20%)  and 
proliferative changes occurred in 2.2%. When duration of diabetes increased to 15 years, 
proliferative changes increased to 16.7%. This correlated with the WESDR study by 
Klein et al., 1989J50  which showed an increase in PDR in individuals with diabetes of 
11-15 years duration. 
Table – 10 : Visual acuity on presentation   
Visual acuity No. of Eyes
Percentage
(%)
6/6 – 6/12 41 22.78
6/18 – 6/36 74 41.11
6/60 – 4/60 40 22.22
3/60 – 1/60 18 10.00
<1/60 7 3.89
On  evaluating  the  visual  acuity  on  the  first  visit  of  90  individuals   with 
retinopathy, 74 (41.11%) had visual acuity between 6/18 – 6/36; 41 (22.78%) had vision 
> 6/12; 40 (22.22%) had vision between 6/60 – 4/60 and 26 (14.45%) were blind with 
visual acuity < 3/60. 
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Table 11 : Visual acuity on presentation  and severity of diabetic retinopathy
Visual acuity
No. of Eyes Percentage (%)
NPDR PDR NPDR PDR
6/6 – 6/12 35 6 30.17 9.38
6/18 – 6/36 52 22 44.82 34.38
6/60 – 4/60 23 17 19.83 26.56
3/60 – 1/60 6 12 5.17 18.75
<1/60 - 7 - 10.93
Figure showing the percentage of Visual acuity on presentation   and severity of 
diabetic retinopathy
In NPDR patients,  30.1% had good visual acuity >6/12 on  initial presentation. 
44.8% had vision between 6/18 to 6/36. Only 5.1% had poor vision <3/60.  In PDR 
patients, 34.38% had vision acuity between 6/18 and 6/36. 36(56.18%) had poor visual 
acuity of <6/60. The poor visual acuity was due to associated preretinal and vitreous 
hemorrhage, extensive exudates and further complications. 
Table – 12 : Risk Factors   
The  various  risk  factors  associated  with  all  the  90  individuals  with 
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nonproliferative and proliferative diabetic retinopathy are analysed and their levels are 
given below as mean and standard deviation. 
Risk Factors   
NPDR
Mean+S.D.
PDR
Mean+S.D.
Total Cholesterol (mg/dl) 211.2+41.6 258.7+50.2
Triglycerides (mg/dl) 156+27.1 176.9+39.8
LDL (mg/dl) 109.4+27.4 149.2+26.1
HDL (mg/dl) 42+5.3 38.90+5.6
Fasting Blood Sugar (mg/dl) 137.5+26.2 180.5+47.2
HbA1c  (%) 8.4+1.2 10.4+1.2
Blood Pressure   – Systolic 142.1+16.28 153.4+14.2
Diastolic 87.0+8.9 96.6+10.6
Duration of Diabetes 8.5+5.5 12.78+4.2
The following table shows the number of individuals with abnormal parameters and the 
range of each parameter in these individuals.
Risk Factors   Range of parameters
Number of 
individuals 
Percentage
(%)
Total Cholesterol (mg/dl) 205-353 59 65.5
Triglycerides  (mg/dl) 161-268 44 41.8
LDL (mg/dl) 101-191 56 62.2
HDL (mg/dl) 21-39 31 35.5
Fasting Blood Sugar (mg/dl) 127-269 67 74.4
HbA1c  (%) 6.1-12.6 83 92.2
Blood Pressure   (mmHg) Systolic 140-180
Diastolic 90-110
58 64.4
Figure showing the percentage of Risk Factors   
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In the total 90 individuals, 59 (65.5%) had hypercholesterolemia and 56 (62.2%) 
had increased LDL cholesterol levels. In 31 (34.4%) individuals the HDL cholesterol 
level was less than 40 mg/dl. In more than two thirds of the individuals (92.2%), there 
was an increased level of glycosylated hemoglobin (HbA1c). An increased fasting blood 
glucose level was measured in 67 (74.4%) individuals. High blood pressure was noted in 
64.4% of individuals.  
Table – 13 : Serum Lipids and Diabetic Retinopathy
Retinopathy Total Cholesterol TGL HDL LDL
NPDR
Mean 211.2 156 42 109.4
S.D 41.6 27.1 5.3 27.4
PDR
Mean 258.7 176.9 38.9 149.2
S.D 50.2 39.8 5.6 26.1
Z Test
Zo 4.80 2.85 2.57 6.71
Ze 1.96 1.96 1.96 1.96
p value 0.000 0.005 0.012 0.000
Figure showing the relation of Serum Lipids and Diabetic Retinopathy
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Analysis by application of  Z test :
Objective : The objective is to test the difference between NPDR and PDR with respect 
to cholesterol. For that initially we assume a null hypothesis that there is no difference 
between NPDR and PDR. We applied the Z test.
Inference : Since Zo > Ze (P<0.05), the null hypothesis is rejected. So there is significant 
difference between the two groups. Thus, even if both NPDR and PDR have elevated 
mean cholesterol, its increase was associated more with development of PDR.  
From the above table, we can observe that p value is significant for triglycerides, 
HDL and LDL also. Thus deranged lipid profile was associated with developing severe 
forms of retinopathy. 
Table – 14 : Fasting Blood Glucose, HbA1c and Diabetic Retinopathy
Retinopathy Fasting Blood Glucose HbA1c
NPDR
Mean 137.5 8.4
S.D 26.2 47.2
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PDR
Mean 180.5 10.4
S.D 1.2 1.2
Z Test
Zo 5.57 7.48
Ze 1.96 1.96
p value 0.001 0.002
Figure  showing  the  relation  of  Fasting  Blood  Glucose,  HbA1c and  Diabetic 
Retinopathy
The mean fasting blood glucose levels were 137.5 in NPDR and 180.5 in PDR. 
Both the groups exhibited an increase level of HbA1c with PDR having a mean of 10.4. 
By applying Z test, p value (<0.05) was significant for both fasting blood glucose and 
HbA1c. Thus, individuals with high baseline values present with more severe retinopathy 
change.  This correlated with the study conducted by Agrawal et al., 2003J43 when HbA1c 
>10, the level of severe retinopathy was greater
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Table – 15 : Ocular Complications
Complications 
Number
(n=90) 
Percentage 
(%)
Total
n %
With complications
Vitreous 
Haemorrhage
14 15.56
Retinal detachment 1 1.1
Vein Occlusion 2 2.23
17 18.89
No complications 73 81.11 73 81.11
Figure showing the percentage of Ocular Complications
Of  the  90  individuals  with  retinopathy,  ocular  complications  occurred  in  17 
(18.89%),  of  which  vitreous  heamorrhage  was  the  most  common  occurring  in  14 
(15.56%).   Branch  vein  occlusion  occurred  in  two  individuals.  Retinal  detachment 
occurred in one. These individuals had poor visual acuity. 
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VARIOUS PRESENTATIONS OF PDR IN FOUR PATIENTS
PDR-HRC (OD) PDR-VITREOUS HAEMORRHAGE (OS)
PDR-NVE (OD) PDR-NVD (OS)
PDR- VITREOUS HAEMORRHAGE (OD) PDR-NVD (OS)
      PDR-ADVANCED (OD) PDR-NVD (OS)
Table – 16 : Systemic Disorders 
Systemic Disorders
Number
(n=90)
Percentage
(%)
Present 59 68.8
Absent 31 31.11
Systemic Disorders
Number
(n=90)
Percentage
(%)
Hypertension 58 64.4
Diabetic Nephropathy 18 20
Coronary Artery 
Disease
12 13.3
Peripheral Neuropathy 4 4.4
Figure  showing the percentage of Systemic Disorders
Majority  of  the  individuals  59  (68.89%),  had  associated  systemic  disorders 
including  systemic  hypertension,  diabetic  nephropathy,  coronary  artery  disease  and 
peripheral neuropathy. 58 individuals had associated systemic hypertension, 18 (30.5%) 
of them had nephropathy, 12 (20%) had coronary artery disease, 4 (6.8%) had peripheral 
neuropathy. 
The  following  picture  depicts  the  various  combinations  of  systemic  disorders 
associated with the study group. 
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FUNDUS PHOTOGRAPH (OD) FUNDUS PHOTOGRAPH (OS)
FLUORESCEIN
ANGIOGRAPHY 
            PRP + GRID (OD)      PRP + GRID (OS)
Table – 17 : Diabetic Retinopathy and treatment of Diabetes mellitus 
Treatment of 
diabetes mellitus
NPDR PDR Maculopathy
n % n % n %
OHA 54 93 3 9.4 19 21.1
Insulin - - 9 28.1 1 1.1
Insulin / OHA 4 6.9 20 62.5 6 6.67
Figure showing the relationship of diabetic retinopathy and treatment of diabetes 
mellitus
In  the  study,  out  of  the  58  subjects  with  NPDR,  54  (93.1%)  were  on  oral 
hypoglycemic agents and 4 (6.9%) were on both insulin and OHA. No NPDR was on 
insulin alone.  Among 32 individuals  of  PDR, 20 (62.5%) were on both insulin  and 
OHA, 9 (28.1%) were on only insulin and three individuals were only on OHA. The 
study by Bodansky et al 1982J44, showed that most cases of PDR occurred in insulin 
taking individuals.  Out of the 26 individuals with maculopathy, 19 (21.1%) were on 
OHA, remaining 7 individuals were either on insulin alone or on both insulin and OHA. 
Table – 18 : Laser in Diabetic Retinopathy and visual acuity 
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Visual acuity Total
Visual 
Improvement Static Worse
n % n % n %
NPDR + Maculopathy 21 9 42.9 11 52.3 1 4.8
PDR + Maculopathy 24 14 58.3 7 29.2 3 12.5
Figure showing the relationship of Laser in Diabetic Retinopathy and visual 
acuity
Among 21 NPDR individuals, 6 received grid, 7 had focal, 1 had PRP and 7were 
given both PRP and grid photocoagulation. Visual improvement occurred in 9 (42.9%). 
In 11 (52.3%) individuals, the vision was stationary. One patient (4.8%) had a failing 
visual  acuity.  In 24 PDR individuals  visual  improvement  occurred in 14 (58.3%),  7 
(29.2%) had the same vision and in 3 (12.5%) the vision worsened. Individuals with 
maculopathy improved more with laser.
64
PDR – PRE LASER PDR – POST LASER
PDR – PRE LASER PDR – POST LASER
MACULOPATHY – PRE LASER MACULOPATHY – POST LASER
PDR – POST LASER POST LASER HAEMORRHAGE
Table – 19 : Laser and progression of retinopathy  
Control on 
Progression Total 
Better Static Worse
n % n % n %
NPDR + 
Maculopathy
21 10 47.6 9 42.9 2 9.5
PDR + 
Maculopathy
24 12 50 9 37.5 3 12.5
Figure showing the relationship of Laser and progression of retinopathy  
Among the NPDR individuals 47.6% had a good control, in 42.9% the retinopathy 
was static and it progressed to severe degrees of retinopathy in two individuals (9.5%). 
Whereas  in  PDR 50% had very  good control  over  progression.  In  three  individuals 
(12.5%)  fresh  neovascularisation  occurred.  Application  of  laser  showed  good 
improvement in the status of retinopathy in PDR individuals. 
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Discussion
DISCUSSION
The  diabetics  attending  the  Eye  department,  Coimbatore  Medical  College 
Hospital, from January 2006 to October 2007 are enrolled and studied for the pattern of 
presentation  of  diabetic  retinopathy.  270  diabetics  attended  the  OPD  of  whom  90 
diabetics had diabetic retinopathy were studied.
 The  predominant age  group affected  with  diabetic  retinopathy  was  51-60 
years. Retinopathy rates were higher (46.67%) in            51-60 years and 23.3% 
of  retinopathy  occurred  in  61-70  years  age  group.  In  a  study  conducted  by 
Khandekar et al., 2003J41, retinopathy rate was commonly documented in 50-59 
years  and  60-69  years.  This  is  confirmed  in  another  study  done  by 
Dandona et al., 1999J42, Agrawal  et al., 2003J43 and Wisconsin epidemiologic 
study on diabetic retinopathy by Klein et al.,             1984 J2J3.
 The gender  wise distribution showed a preponderance for male sex. The ratio 
being  1.6  :  1  most  of  the  male  sex  was  associated  with  severe  forms  of 
retinopathy. This correlated with the study by Bodansky et al., 1982  J44 which 
showed the ratio as 2:1 and Rema et al., 2005J45. A similar male predominance 
has been reported by Dandone et al 1999J42 and Kohner et al 1998J46. 
 In our study, 45.5 % of the individuals had family history of diabetes. 39% of 
NPDR and 60% of PDR had a positive family history. In the above group, there 
was  a  higher  risk  of  proliferative  retinopathy.  This  correlated  with  studies 
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conducted by Mohan et al 1986J47 and Ramchandran et al 1992J48. 
   Magnitude of retinopathy 
Out  of  270  diabetic  individuals  90  (33.33%)  had  retinopathy.  This 
comprised  of  58  (64.44%)  individuals  of  NPDR  and  32  (36.56%)  of  PDR. 
NPDR was the most common retinopathy seen. This correlated with the studies 
conducted by Agrawal et al            2003 J43 and Narendran et al 2002 J49.
In our study, among  the 32 PDR individuals,  most (21) were with high risk 
characteristics. Among 90 retinopathy individuals, 26 (9.63%) had maculopathy. 
This  can be compared with a  hospital  based study done by Khandekar  et  al 
2003J41 Maculopathy was associated more commonly with NPDR individuals 
(73.08%) than with PDR (2.59%). 
 Duration of diabetes 
When  duration  of  diabetes  was  less  than  5  years,  only  20  individuals 
(22.2%) had retinopathy. With duration >10 years, 45.44% had retinopathy of 
varying severity. 
In this study individuals with less than 5 years of diabetes, 18 (20%) had 
NPDR and only 2 (2.2%) had PDR. At 6-10 years period NPDR was more, 
accounting for 33.3% and as the duration of the diabetes progressed, PDR was 
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on the rise reaching a peak of 16.7% in 11-15 years. Most of the mild NPDR had 
less than 5 years of diabetes and moderate NPDR had 6-10 years of diabetes. 
After 15 years of diabetes PDR was more than NPDR (6.7% vs 3.3%). This 
correlated with the WESDR by Klein et al 1989J50 which showed an increase in 
PDR when diabetes is around 15 years. 
Thus individuals with long standing diabetes, there is an increased risk and 
severity  of  retinopathy  and  maculopathy  which  correlated  with  the  study 
conducted by Eckhard Zander et al  2000 J51. 
 Visual acuity :  On first  visit  most  individuals (74, 41.1%) had visual  acuity 
between  6/18-6/36  and  14.44%  had  less  than  3/60.  In   NPDR  30%  had 
presenting visual acuity >61/12 whereas, in PDR, only 9.3% had vision >6/12. 
In the later group 56.2% had visual acuity <6/60. This depicts the intense impact 
of the severity of retinopathy on visual acuity. 
 Lipids : In our study the mean baseline total cholesterol, LDL, TGL and HDL 
levels in NPDR were 211.29 mg/dl ,109 mg/dl, 156 mg/dl, 4.2 mg/dl and that in 
PDR were 258.6 mg/dl,  149.25, 176.8 mg/dl and 38.9 mg/dl respectively. 
Cholesterol and LDL were higher in both NPDR and PDR. HDL was lower 
in PDR. This correlated with Dornan et al., 1982J52 which showed association of 
PDR with raised cholesterol and LDL. Klein et al 1988 and Chew et al 1996 J6 
showed a significant trend for increased severity of retinopathy with an increase 
in cholesterol.
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 Hyperglycemia  : In  diabetics  with  NPDR,  the  mean  baseline  fasting  blood 
glucose, HbA1c were 137.5 mg/dl, 8.4% and that of PDR were 149.25 mg/dl, 
10.4% respectively. 
Hyperglycemia  was an associated  factor  in  both the groups.  Klein et  al 
1984  J2,3 and DCCT study (1993) showed the similar  findings.  Agrawal et  al 
2003J43 stated that if HbA1c  > 10, prevalence of severe retinopathy was more. In 
the WESDR, if baseline HbA1c was between 10.1– 11.5%, PDR was more.
Date  from  the  WESDR  showed  that  HbA1c was  associated  with  the 
incidence  and progression  of  retinopathy,  progression  to  PDR and  incidence 
CSME (Klein et al., 1988, 1994 J53,54).
 The mean systolic and diastolic BP in NPDR were 142.06+2.21 and 81.03+1.16 
respectively.  The mean systolic  and diastolic  BP in  PDR were 15.4+2.5 and 
96.6+1.8  mmHg respectively.  In  both  the groups  the  systolic  BP was raised 
whereas PDR was associated with an increase in diastolic BP also. 
Thus, PDR was associated hypercholesterolemia increased LDL, increase 
mean  baseline  fasting  blood  glucose  &  HbA1c and  high  diastolic  BP  which 
correlated with Ossama et al 1998 J56 and UKPDSJ7.  
 Of the 90 individuals, 15.5% had vitreous haemorrhage, one individual (1.1%) 
had RD and two had BRVO.
 In our study,  we had 59 (68.8%) with systemic disorders.  Hypertension was 
present alone in 34 (57.6%) and in conjunction with nephropathy in 12 (20.3%) 
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and CAD in 7 (11.8%). All the 4 (6.8%) individuals had all the four disorders, 
out of which 2 were on insulin. This correlated with the study conducted by 
Tasanee et al 2007J57 which showed 61.8% with hypertension. 
 Of  the  33  individuals  on  insulin,  29  had  PDR  and  4  (4.4%)  had  NPDR. 
Treatment with insulin is associated with more severe progressive retinopathy 
(Agrawal et al 2003 J43). 
 A total of 45 individuals with PDR and NPDR, maculopathy were subjected to 
laser  photocoagulation.  Of  them,  23  (51.1%)  had improvement  in  the  visual 
acuity and 22 (4.88) had stable visual acuity. 
22 had good control over progression of retinopathy, 18 showed no further 
progression and only 5 showed progressive changes. This effectiveness on laser 
in  improving  visual  acuity  and  checking  the  progression  of  retinopathy  by 
ETDRSJ21 and DRS J29 J37.  
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Summary
SUMMARY
 Diabetic retinopathy more commonly presented in 51-60 years and a significant 
number occurred in the next decade (61-70 years).
 Males were commonly affected with diabetic retinopathy than females. 
 Most of the individuals with the PDR had a positive family history of diabetes. 
There is an increased risk of proliferative changes in individuals with a positive 
history.
 Of all  the diabetics reported 33% had diabetic retinopathy. NPDR occurred in 
majority of the diabetes. In PDR group, high risk characteristics  occurred more. 
Maculopathy occurred in 9.63%.
 On comparing the duration of diabetes, in the study group, PDR  was reported in 
more than 23.4% as the duration of diabetes increased to more than 10 years. 
Duration of diabetes is strongly associated with the incidence and progression of 
retinopathy. Increased duration of diabetes had an increased risk of retinopathy.
 Majority of the NPDR (42.82%) had a presenting visual acuity greater than 6/36. 
The low vision in NPDR is associated with maculopathy. In PDR 34.38% had 
vision between 6/18 to 6/36 and 56.2% had poor visual  acuity  of <6/60. This 
shows that proliferative changes are associated with deteriorating visual acuity.
 Hypercholesterolemia,  elevated  LDL,  TGL  and  reduced  HDL  levels  were 
associated with PDR. Elevated cholesterol and LDL levels were associated with 72
NPDR. Diabetics with deranged lipid profile were more prone for severe diabetic 
retinopathy, and increased incidence of maculopathy. 
 Hyperglycemia manifested as elevated mean baseline fasting blood glucose and 
HbA1c is  a  significant  risk  factor  in  the  development  and  progression  of 
retinopathy. High blood pressure is strongly associated with retinopathy.
 Vitreous haemorrhage was the most common ocular complication. hypertension, 
nephropathy and CAD were commonly associated systemic disorders. 
 90% of Proliferative Diabetic Retinopathy were on insulin. 
 Laser photocoagulation improved visual  acuity in 51.1% and kept the progression 
of retinopathy under control in nearly half of the individuals. 
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Conclusion 
CONCLUSION
• Diabetic retinopathy is more common after 50 years of age.  
• There is a preponderance of males for diabetic retinopathy.
• Individuals  having  positive  family  of  diabetes  have  progressive  and  severe 
retinopathy changes.
• 33% of individuals had retinopathy and among them NPDR is the most common 
form of retinopathy. 
• Increased  duration  of  diabetes  is  associated  with  increased  risk  of  developing 
retinopathy. 
• Abnormal level of lipids, abnormal fasting blood glucose and HbA1c and elevated 
blood pressure are important risk factors of diabetic retinopathy. 
• Diabetic retinopathy causes a morbid decrease in vision.
• Common complication  associated  is  vitreous  haemorrhage  and  common systemic 
disorder associated is systemic hypertension followed by nephropathy. 
• Periodic ocular examination in all diabetics should be carried out. 
• Early diagnosis of maculopathy and its early treatment with laser reduces significant 74
visual loss. 
• Diabetic  retinopathy is  a  preventable  cause  of  blindness especially  in  developing 
countries. Timely intervention with laser treatment saves the individual from severe 
visual loss by controlling the progression of retinopathy.
75
Bibliography
BIBLIOGRAPHY
Text book references (S)
1. System of Ophthalmology.  Steward Duke Elder vol X diseases of retina © Mosby 
1967; 409 – 408.  
2. Stephen J Ryan text book on retina Vol 2 ; 3rd ed, section – 5, 1259 to 1349.
3. Oxford text book of Ophthalmology Vol 2 © Easty and Sparrow 709 -722.  
4. Albert  and  Jakobeic  principles  and  practice  of  Ophthalmology  2nd ed,  Vol  2,  © 
Saunders 2000; 1901 - 1936. 
5. Paul M Dodson, Jonathan M Gibsol, Ema E Kritziyer.  Clinical ratinopathies 1st ed, 
© Chapman and Hall 1995; 36 – 53.
6. American Academy of Ophthalmology.  Basic and clinical Science course.  Sec – 12, 
©  AAO Retina and Vitreous 2006; 99 – 119.
7. David J Apple Ocular Pathology.  Clinical Application and Self assessment 5th ed, 
1998; ©  Mosby 374- 381.
8. Hem K Tewar, Lalit  Verma.  Fluorescein Angiography - A user's manual  2nd ed, 
2003; 59-84.
9.  Hamilton's Management of Diabetic Retinopathy 2003; 1-287 © BMJ   Publishing 
Group.
76
10. Gholam  A Peyman, Morton F Goldberg Principles and Practice of Ophthalmology 
vol2. 
11. Guyer, Yannuzi and Chang. Retina/ vitreous/ Macula Chapter © 26; 316 – 344.
12. Harrison's Principles of internal Medicine 16th ed 2005; A1 – A7© The Mc Graw Hill 
Company. 
Journals (J)
1. Friedenwald J S, diabetic retinopathy Am J Ophthalmol 1950; 33:1187-1199. 
2. Klein  R,  Klein  BE,  Moss  SE,  Davis  MD,  Dmets  DL;  Wisconsin  Epidemiologic 
Study on Diabetic Retinopathy II.  Prevalence and risk factors of diabetic retinopathy 
when age at diagnosis < 30 years.  Arch Ophthalmol 1984; 105: 520 -526.
3. Klein R,  Klein BE,  Moss SE,  Davis  MD, Dmets DL.  Wisconsin Epidemiologic 
Study  on  Diabetic  Retinopathy  III.   Prevalence  and  risk  factors  of  diabetic 
retinopathy when age at diagnosis ≥ 30 years.  Arch Ophthalmol 1984; 102 (4): 527 
-532.
4. Diabetes control and complications Trial Research group: Perspective in Diabetes: 
The  relationship  of  glycemic  exposure  (HbA1c)  to  the  risk  of  development  and 
progression of retinopathy in the Diabetes Control and Complication Trial, Diabetes 
77
44: 1996 968 -983.
5. Davis  M,  Fisher  M,  Gangnon   R  ,  Barton   F,  Aiello  L,  Chew  E,  Ferris  III  F, 
Knatteruel and the Early Treatment   Diabetic Retinopathy Study Research Group: 
Risk factors for the high – risk proliferative  diabetic retinopathy and severe visual 
loss: ETDRS Report no: 18, Invest Ophthalmol Vis Sci 39: 1998; 233 – 252.
6.  Chew EY, Klein ML, Ferris FL III et al., and the ETDRS research group.  Early 
Treatment  Diabetic  Retinopathy  Study  Report  no:  22.   Association  of  Elevated 
Serum  lipid  levels  with  retinal  hard  exudates  in  diabetic  retinopathy.   Arch 
Ophthalmol 1996; 114           1079 – 1084. 
7.  United Kingdom prospective diabetes study group.  Tight blood pressure control and 
risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 
38); Br Med J 1998; 317: 703 to 713. 
8. Chew  EY,  Mills  JL,  Metzgee  et  al:  Metabolic  control  and  progress  of  diabetic 
retinopathy.   The  diabetes  in  Early  Pregnancy  study,  National  Institute  of  Child 
Health and Human Development, Diabetes care 1995; 18:631-637.
9. Baker R, Rand L, Krolewski A et al, Influence of HLA –DR phenotype and myopia 
in risk of  nonproliferative and proliferative diabetic retinopathy.  Am J Ophthalmol 
1986; 102: 693 – 700.
10.Jain  IS,  Luthra,  KL,  Das  T:  Diabetic  Retinopathy  and  it  relation  to  errors  of 
refraction.  Arch Ophthamlol 1996; 77: 59- 60.
11.Brownlee et al: The Biochemistry of the complications of diabetes mellitus Annu 
Rev Biochemist 1981; 50: 385- 432.
12. Kwioki M, Voest EE, Ameno.  Reactive Oxygen intermediates Increase vascular 
endothelial growth factor expression J Clin Invest 1996; 98: 1667-1675.
13. Williamson  JR,  Chang  K,  Franzos  M,  Hasan  ES,  Ido  et  al:  Hyper  glycemic 
pseudohypoxia and diabetic complications, Diabetes 1993; 42: 801- 813.
14. Kador  PF,  Akagi  Y,  Takahashi  Y,  et  al;  Prevention  of  retinal  vessel  changes 
associated  with  diabetic  retinopathy  in  galactose  feed  dogs  by  aldose  reductase 
inhibitorys, Arch Ophthalmol 1990; l 108: 1301 -1309.
15. Xia et al: Characterisation of the mechanism for the chronic activation of diacyl – 
Glycerol- Protein Kinase C pathway in diabetes and hyper Galactosemia, Diabetes 
1994; 43: 1122- 1129.
16. Aiello LP, Northrup JM, Keift BA, Takagi H et al: Hypoxic regulation of vascular 
endothelial growth factor in retinal cells, Arch Ophthalmol 1995;113:1538-1544. 
17.Engerman RL and Colquhoun PJ; Epithelial and mesothelial basement membrane in 
diabetic patient, Diabetologia 1982; 23:521- 524
18.Cogan  DG,  Toussaint  D,  and  Kuwabara  T:Retinal  Vascular  patterns  IV.Diabetic 
retinopathy,Arch Ophthalmol 1961;66:366-378.
19.Kuwabara T and Cogan DG:Retinal  vascular  patterns.I.Normal  architecture,  Arch 
Ophthalmol 1960;64:904-911.
20.Taniguchi Y:Ultrastructure of newly formed blood vessels in diabetic retinopathy, 
Jpn J  Ophthalmol 1976; 20: 19-31.
21.Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographi 
risk  factors  for  progression  of  diabetic  retinopathy  ETDRS  report  no:  12  Br  J 
Ophthalmol 1991; 98;              823- 33.
22.Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for 
diabetic macular edema, ETDRS report no 1, Arch ophthalmol1985; 103:1796-1806.
23.Klien  R,  Klein  BE,  Moss  SE.   The  Wisconsin  Epidemiologic  study  of  diabetic 
retinopathy IV. Diabetic macular edema.  Ophthalmology 1984;91: 1464 – 1486. 
24.Ashton N, Little H, Jack R, Patez A, and Forsham P et al: Pathogenesis of diabetic 
retinopathy  Am J Ophthalmol 1983; 68: 732 – 743.
25.Michelson: The mode of development of the vascular system of the retina with some 
observation on its significance for certain retian diseases: Trans Ophthalmol Soc UK 
1948; 68:137 -180.
26.Patz  A:  Clinical  and  Experimental  studies  on  retinal  neovascularisation  Am  J 
Ophthalmol 1952;94: 715- 743.
27.Davis  M  et  al;  Vitreous  contraction  in  proliferative  diabetic  retinopathy  Arch 
ophthalmol 1965; 74:741-751. 
28.Taylor E and Dobree J, et al., proliferative retinopathy, site and size of initial lesions, 
Br J ophthalmol 1970; 54: 11-18.
29.Diabetic  retinopathy study research group: design,  methods and base line results. 
DRS report no:6, Invest Ophthalmol Vis Sci 1981; 21: 149-209.
30.Dobree J et al: Proliferative diabetic retinopathy: Evolution of the retinal lesions Br J 
ophthalmol 1964; 48: 637- 649
31.Bresnick G, Haight B and De Venecia G: Retinal wrinkling and macular heterotopia 
in diabetic retinopathy, Arch Ophthalmol 1979; 97:1890-1895.
32.Beetham W et al :Visual prognosis of diabetic retinopathy,                   Br J 
Ophthalmol 1963;47:611-619.
33.Ramsay  W,  Ramsay  R,  Purple  R  and  Knowbloch  W;  Involutional  diabetic 
retinopathy, Am J Ophthalmol 1977; 84:851-858.
34.De Venecia G, Davis M and Engerman R; Clinicopathologic Correlations in diabetic 
retinopathy  :  Histology  and  Flurescein  angiography  of  microaneurysms.  Arch 
Ophthalmol 1996;                1306-1310.
35.  Early  treatment  Diabetic  Retinopathy  Study  Research  Group.  Report  no  :
13.Fluorescein Angiographic risk factors for  progression of diabetic retinopathy Br J 
Ophthalmol 1991;98;834-840.
36. Bresnick GH, Condit, Syrjalala S et al: Abnormalities of foveal avascular zone Arch 
Ophthalmol1984;102:1286-129 35. 
37.Diabetic  Retinopathy  Study  Research   Group:  Photocoagulation  treatment  of 
proliferative diabetic retinopathy. Clinical application of DRS findings. DRS report 
no:8 Ophthalmology1981;88:583-600.
38.Rice T, Michels R, Rice E: Vitrectomy for diabetic traction retinal detachment 
involving macula. Am J Ophthalmol 1983;95:222-331.
39.Aaberg T: Clinical results in vitrectomy for diabetic traction retinal detachment Am J 
Ophthalmol 1979; 88:246-253.      
40.Executive  summary  of  the  third  report  of  the  National  Cholesterol  Education 
Program (NCEP) expert panel on detection, evaluation and treatment of high blood 
cholesterol in adults (ADULT TREATMENT PANELIII):JAMA 2001;285:2486.
41. Khandekar R J, Al Lawati, A J Mohammed and A AC Raisi. Diabetic retinopathy in 
Oman; a hospital based study                             Br J Ophthalmol 2003;87:1061-1064.
42. Dandona L, Dandona R, Naduvillath JJ, Mc Carty CA, Rao GN.  Population based 
assessment of diabetic retinopathy in an urban population in Southern India Br J 
Ophthalmol 1999;83:937-940.
43. Agrawal RP, Ranka M, Beniwal R, Gothwal SR, Jain GC, Kochar DK, Kothari RP. 
Prevalence of diabetic retinopathy in diabetics in relation to risk factors:  hospital 
based study Diabetes 2003;             23:16-19.
44.Bodansky HJ, Cudworth AG, Whitelock R A, Dobree JH: Diabetic retinopathy and 
its relation to type of diabetes: review of a retinal clinic population.Br J Ophthalmol 
1982;66:496-499.
45. Rema M, Premkumar S, Anitha B, Deepa R et al. Prevalence of diabetic retinopathy 
in urban India: the Chennai Urban Rural Epidemiology Study. Invest Ophthal Vis Sci 
2005;46:2328-2333.
46.Kohner EM, Aldington SJ, Stralton IM et al, Diabetic retinopathy at diagnosis of 
NIDDM  and  associated  risk  factors.  United  Kingdom  Prospective  Diabetic 
retinopathy Study 30,Arch Ophthalmol 1998;116:297-353.
47.Mohan V, Sharp PS, Aber V, Mather HM, Kohner EM. Family histories of Asian 
Indians and European diabetes patients, Pract Diabetes 1986;3:254-256.
48. Ramchandran  A,  Snehalatha  C,  Dharmaraja  D,  Viswanathan  M.  Prevalence  of 
glucose intolerance in Asian Indians. Diabetes Care 1992;15:1348-1355.
49.Narendran V, John RK, Raghuram RK, Ravindran RD, Nirmalan PK, Thulasiraj RD. 
Diabetic retinopathy among self-reported diabetics in Southern India: a population 
based assessment.Br J Ophthalmol 2002;86:1014-1018.
50.Klein R,  Klein BE,  Moss SE,  Davis  MD, Demets DL, Wisconsin Epidemiologic 
Study of Diabetic Retinopathy IX. Four year incidence and progression of diabetic 
retinopathy when age at diagnosis, 30 yrs Arch Ophthalmol 1989;107;237-243.
51.Eckhard Zander, Sabina H, Beate B et al, Maculopathy in patients with type I &type 
II diabetes: association with risk factors.Br J Ophthalmol 2000;84:871-876.
52.Dornan TL, Carter RD, Bron HJ. LDL Cholesterol and association with severity of 
diabetic retinopathy Diabetolgia Latina  1982.
53.  Klein R, Klein BE, Moss SE, Davis MD, Demets DL, Glycosylated hemoglobin 
predicts  the  incidence  and  progression  of  diabetic  retinopathy  JAMA 
1988;260;2864-2871.
54.Klein R, Klein BE, Moss SE, Cruickshanls KJ. Relationship of hyperglycemia to the 
long  term incidence and progression of diabetic retinopathy Arch Ophthalmol 1994; 
154: 2169-2178.
55.Diabetes Control and Complications Trial Research Group. The effect of intensive 
treatment of diabetes on the development and progression of long term complications 
in IDDM England J Med 1993;329: 977-986.
56. Ossama  A  W,  Haddad  El,  Saad  M  K.  Prevalence  and  risk  factors  for  diabetic 
retinopathy among Omani diabetics  Br J Ophthalmol 1998;82:901-906.
57. Tasanee  S T Smith, John Szetu and Rupert R Bourne. The prevalence and severity of 
diabetic retinopathy, associated risk factors and vision loss in patients registered with 
type II diabetes in Luganville Br J Ophthalmol 2007;91:415-419.
Appendix 
PROFORMA
                                    
Name :
Age :
Sex :
Hospital no                                      :
Address                                             :
Telephone no                                    :
Complaints                                       :
Defective vision            :               RE/LE/Both
Duration       :
Onset           :                gradual/sudden
Any other complaints :
Past history
h/o similar episodes      :
nature of treatment  :
              h/o diabetes                   :
age of onset             :
duration                   :
nature of treatment :
h/o hypertension           :
                           duration :
                   h/o heart disease         :
duration                   :
                   h/o systemic disorders  :
Ocular examination RE LE
              Visual acuity :
IOP :
Lids :
Conjunctiva :
Cornea :
AC :
Pupil :
Lens :
Retinoscopy :
Subjective :
BCVA :
Fundus examination :
Direct - media        :
                                       Disc          :
Vessels :
Macula    :
Retina     :
Indirect-  media    :
Disc          :
Vessels     :
Macula    :
Peripheral retina :
S/L with +78 D     :
Fundus Fluorescein Angiography  :
Diagnosis                                           :
Investigations
Blood pressure          :
Fasting blood glucose :
HbAIC                       :
Cholesterol                 :     
TGL                          :
HDL                         :
LDL                          :
Blood urea                :
Serum creatinine      :
ECG                          :
  Urine-albumin          :
  Sugar            :
Deposits        :
Photocoagulation                         
PRP                          :
Focal                      :
Grid                         :      
Follow-up 
Fundus :
Slit Lamp  : 
ABBREVIATIONS 
M                -  Male
F                 -  Female
Dur             - Duration in years
VA             -  Visual Acuity
        BCVA        -  Best corrected visual acuity
RE              -  Right eye
LE              -  Left eye
BP              -  Blood pressure
Chol           -  Cholesterol
TGL              -  Triglycerides
HDL              -  High density lipoproteins
LDL              -  Low density lipoproteins
SrCr             -  Serum Creatinine
FBG - Fasting Blood Glucse
HbA1C       -  Glycosylated Hemoglobin
SHT            -  Systemic hypertension
DN             -  Diabetic Nephropathy
CAD           -  Coronary Artery Disease
PN               -  Peripheral Neuropathy 
Mild NPDR -  Mild nonproliferative diabetic retinopathy
Mod NPDR -  Moderate nonproliferative diabetic retinopathy
Sev NPDR  -  Severe nonproliferative diabetic retinopathy
V S NPDR  -  Very Severe  nonproliferative diabetic retinopathy 
NH PDR     -  Non High risk Proliferative diabetic retinopathy 
HR PDR     -  High risk Proliferative diabetic retinopathy    
COM          -  Complications
FFA            - Fundus Fluorescein Angiography
CD              - Capillary Dropouts
 DL              -  Diffuse Leaks
BF              -  Blocked Fluorescence
FL              -  Focal Leaks
LNV          -  Leaking New Vessels
NV            -  No View
ISCH - Ischaemia
PRP           -  Pan retinal photocoagulation
G               -  Grid
F                -  Focal 
I                 -  Insulin
O               -  Oral
I/O             -  Insulin / Oral        
RE LE RE LE Chol TGL HDL LDL SHT DN IHD PN RE LE RE LE RE LE RE LE
1 Subramani 32 M 10 6/36 6/60 6/18 6/60 + 130/80 275 157 41 166 30 0.9 183 11 - - - - Mod  NPDR NH PDR - - - CD,BF,NFAZ LNV,NFAZ PRP 6/18 6/60 I
2 Rajendran 51 M 15 6/24 5/60 6/24 5/60 - 160/100 239 95 36 187 35 1.0 250 11.5 + - - - Mod  NPDR NH PDR - + - CD, BF CD,DL, LN PRP, G 6/24 6/36 I/O
3 Syed Mohammed 51 M 7 6/9 6/6 6/9 6/6 - 140/90 146 163 42 93 28 0.8 179 9 + - + - Mod  NPDR Mod NPDR - - - CD,BF,NFAZ BF,NFAZ - 6/9 6/6 O
4 Dakshinamorthy 44 M 12 HM 6/60 HM 6/60 + 130/80 306 187 35 141 24 0.8 239 12 - - - - HR PDR NH PDR - + VH NV DL,LNV,CSME PRP, G HM 6/24 I/O
5 Chellappan 50 M 9 6/60 6/60 6/60 6/60 + 150/90 295 148 30 156 63 4.6 206 11 + + - - NH PDR NH PDR - - - CD,BF,LNV CD,BF,LNV PRP 6/36 6/60 I/O
6 Sakkariya 67 M 25 6/36 6/60 6/24 6/60 + 160/96 198 153 40 96 33 1.0 197 10 + - - - Sev NPDR VS NPDR - - - CD,BF,NFAZ CD,BF,NFAZ PRP 6/24 4/60 O
7 Maruthachalam 55 M 13 6/36 HM 6/18 HM + 130/80 189 165 44 129 56 3.8 193 10 - + - - HRPDR HR PDR - - VH BF,NFAZ,LNV BF,NFAZ,LNV PRP 6/18 HM I
8 Ravi 42 M 3 6/60 5/60 6/60 5/60 + 160/100 216 162 40 137 28 0.5 256 8.6 + + - - NH PDR NH PDR - - - BF,NFAZ,LNV BF,NFAZ,LNV PRP 6/60 6/36 I
9 Jothi 58 F 1 6/12 6/36 6/6 6/9 - 140/90 183 146 48 86 30 1.0 110 5.7 + - - - Mild NPDR Mild NPDR - - - BF,NFAZ BF,NFAZ - 6/6 6/9 O
10 Chandrasekar 54 M 13 6/36 6/36 6/36 6/36 - 160/90 210 163 45 171 28 0.8 130 9 + - + - Sev NPDR Sev NPDR + + - CD, DL, BF CD, DL, BF G 6/36 6/36 O
11 krishnasamy 53 M 5 6/36 6/24 6/24 6/18 + 150/100 198 138 46 105 24 0.9 172 7.7 + - + - Sev NPDR Mod NPDR - - - CD,BF,NAZ CD,BF,NFAZ - 6/24 6/18 O
12 Palaniammal 49 F 15 5/60 3/60 5/60 3/60 + 160/90 230 168 35 71 30 1.0 169 9 + - - - Sev NPDR Sev NPDR + + - CD,CSME CD,CSME F 6/60 6/60 O
13 Moideen kutti 65 M 9 6/24 6/60 6/24 6/36 - 150/90 187 113 43 84 28 0.8 123 8 - - - - Mod  NPDR Mod NPDR - - - CD,NFAZ, BF CD,NFAZ,BF - 6/24 6/36 O
14 Palaniammal 62 F 8 1/60 6/12p 1/60 6/12 + 150/100 272 163 35 163 30 0.6 115 11.2 + - - - HR PDR Mod NPDR - - VH BF,LNV CD,BF,NFAZ - 1/60 6/12 I/O
15 Aleema 52 F 6 6/12 6/12 6/12 6/9 - 140/90 220 158 39 96 24 1.0 98 10.1 + - - - Mod  NPDR Mod NPDR - - - BF,NFAZ BF,NFAZ - 6/12 6/9 O
16 Parvathy 55 F 5 6/60 6/60 6/60 6/60 - 140/90 190 151 44 98 32 0.7 136 9.4 + - - - Mod  NPDR Mod NPDR + + - CD,DL,NFAZ CD,DL,NFAZ G 6/60 6/60 O
17 Jayaprakash 45 M 7 6/18 6/24 6/9 6/12 - 130/80 275 205 42 127 28 1.2 147 5.9 - - - - Mod  NPDR Mod NPDR - - - CD,NFAZ, BF CD,NFAZ - 6/9 6/12 O
18 SivaKumar 42 M 11 3/60 1/60 3/60 1/60 + 180/100 298 268 47 137 27 0.9 269 10.9 + - - - NH PDR HR PDR - + VH BF,NLV CD,DL,LNV PRP,G 3/60 6/36 I/O
19 Maria matilda 62 F 12 CFCF 6/60 CFCF 6/24 + 150/100 277 217 43 117 30 0.8 175 12 + - - - HR PDR Sev NPDR - - VH NV CD,BF,NFAZ PRP CFCF 6/24 I/O
20 ArunachalGoundar 60 M 15 4/60 3/60 6/36 3/60 - 160/110 217 220 21 128 34 0.6 152 9.8 + - - - VS NPDR HR PDR + - - CD,DL CD,BF,LNV PRP,G 6/36 6/60 O
21 Rajabunisha 48 F 7 6/24 1/60 6/12 1/60 + 150/100 297 191 30 91 26 0.7 141 11.7 + - - - Mod  NPDR HR PDR - - VH CD,BF,NFAZ LNV,CD,BF - 6/12 1/60 O
22 Rukmani 55 F 13 2/60 6/36 2/60 6/36 - 130/84 230 185 41 76 28 0.8 130 9 - - - - Sev NPDR Sev NPDR + - - CD,FL,NFAZ CD,NFAZ F 2/60 6/36 O
23 Sampoornam 58 F 8 6/60 1/60 6/36 1/60 + 140/80 189 190 40 167 24 1.0 125 9 - - - - Sev NPDR NH PDR - + - CD,BF,NFAZ CD,BF,CSME PRP,G 6/36 4/60 O
24 Palaniappan 50 M 2 6/36 6/36 6/36 6/36 - 150/90 229 189 34 98 30 0.9 136 9.6 + - - - Sev NPDR Sev NPDR - - - BF,NFAZ BF,NFAZ - 6/36 6/36 O
25 Mariammal 55 F 1.5 6/24 6/9P 6/9 6/9 - 126/78 183 134 48 115 26 0.8 111 7.5 - - - - Mod  NPDR Mod NPDR - - - CD,BF,NFAZ CD,BF,NFAZ - 6/9 6/9 O
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26 Nagammal 54 F 9 6/60 6/60 6/24 6/18 - 158/90 282 153 44 97 32 1.0 102 9 + - + - Sev NPDR Sev NPDR - - - BF,NFAZ BF,NFAZ - 6/24 6/18 O
27 Basha 52 M 13 6/60 6/36 6/36 6/24 + 140/80 193 186 42 135 28 0.9 151 8.6 - - - - NH PDR Sev NPDR - - - BF,LNV,NFAZ CD,BF,NFAZ PRP 6/60 6/36 I/O
28 Bagiam 58 F 8 6/36 6/24 6/36 6/24 - 142/100 148 164 40 164 24 1.2 130 7.5 + - - - Sev NPDR Sev NPDR - - - BF,NFAZ BF,NFAZ - 6/36 6/24 O
29 Padmavathy 46 F 8 6/36 5/60 6/24 5/60 - 140/90 214 157 50 112 28 0.8 141 8 + - - - Mod  NPDR Mod NPDR - + - CD, NFAZ CD,DL,BF G 6/24 6/36 O
30 Subramani 33 M 15 5/60 6/36 5/60 6/36 + 150/100 264 138 48 144 52 3.6 168 12.2 + + - - NH PDR HR PDR - - - CD,LNV,BF CD, LNV, BF PRP 5/60 6/36 I/O
31 Muruganantham 55 M 17 1/60 6/9 1/60 6/9 - 160/100 270 187 33 173 48 2.6 174 9.8 + + - - HRPDR Sev NPDR - - RD LNV,BF BF,NFAZ - 1/60 6/9 I/O
32 Anthonysamy 63 F 12 6/60 4/60 6/60 4/60 + 180/100 236 199 43 94 32 1.0 116 8 + - - - Mod  NPDR Mod NPDR + + - CD,FL,NFAZ CD,FL,NFAZ F 6/36 6/60 O
33 Jilthre 61 F 10 6/36 6/60 6/24 6/60 - 162/90 269 186 35 82 28 0.8 135 9.9 + - - - Mod  NPDR Mod NPDR - + BRVO CD, NFAZ CD,NFAZ,DL,BF G 6/24 6/60 O
34 Dhandapani 63 M 20 6/60 6/60 6/36 6/36 + 170/110 230 156 49 128 53 3.6 188 11.7 + + + + HR PDR HR PDR - - - LNV,BF,NFAZ LNV,BF,NFAZ PRP 6/18 6/18 I/O
35 Kameshwari 42 F 3 6/9 6/18 6/9 6/12 - 110/80 142 120 45 77 26 0.9 140 7.1 - - - - Mild NPDR Mild NPDR - - - CD,NFAZ, BF CD,NFAZ - 6/9 6/12 O
36 John 63 M 20 6/60 3/60 6/60 3/60 + 180/100 284 156 43 142 28 1.0 228 12 + - + - HR PDR HR PDR - - VH LNV,BF LNV,BF PRP 6/60 3/60 I/O
37 Ponnuraj 48 M 2 6/24 612 6/12 6/12 - 130/80 166 140 36 104 32 0.9 145 7 - - - - Mod  NPDR Mod NPDR - - - CD,NFAZ, BF CD,NFAZ - 6/12 6/12 O
38 Devasagayam 55 M 15 6/18 6/18 6/18 6/18 + 140/100 147 139 35 148 26 0.8 151 9.2 + - - - HRPDR VS NPDR - - - LNV,BF,NFAZ CD,BF,NFAZ PRP 6/18 6/18 I
39 Chandrasekar 58 M 9 2/60 5/60 2/60 5/60 - 130/86 212 180 43 98 30 0.9 136 8 - - - - VS NPDR VS NPDR + - - CD, DL, NFAZ CD, NFAZ PRP, G 6/160 6/60 O
40 Pushpam 57 F 7 6/36 HM 6/36 HM - 160/90 278 150 47 136 28 1.2 207 9.4 + - - - NH PDR HR PDR - - VH LNV,BF LNV,BF PRP 6/60 HM O
41 Vishwanathan 53 M 12 1/60 6/12 1/60 6/9 + 150/100 264 184 40 191 29 0.8 246 10.7 + - - - HR PDR NH PDR - - VH LNV,BF LNV,BF PRP 1/60 6/9 I/O
42 Saraswathi 62 F 5 6/24 6/9 6/9 6/6 - 110/70 205 148 50 79 34 1.2 151 5.5 - - - - Mild NPDR Mild NPDR - - - CD,NFAZ, BF CD,NFAZ - 6/9 6/6 O
43 Celine 65 F 6 6/36 6/9 6/36 6/9 - 150/80 178 152 42 87 26 0.8 143 7.9 - - - - Mod  NPDR Mod NPDR - - - CD,BF,NFAZ CD,BF,NFAZ - 6/36 6/9 O
44 Selvaraj 49 M 10 3/60 5/60 3/60 5/60 + 156/100 256 181 32 169 68 4.3 127 10 + + + + VS NPDR Mod NPDR + + - CD,DL,CSME CD,DL,CSME PRP G 6/60 6/36 I/O
45 Pushpa 50 F 9 6/9 6/18 6/9 6/12 - 140/90 184 105 47 107 30 0.9 124 7.3 + - - - Mod  NPDR Mod NPDR - - - CD,BF,NFAZ CD,BFNFAZ - 6/9 6/12 O
46 Paulraj 68 M 1.5 5/60 6/24 6/60 6/60 - 150/100 215 240 38 131 48 2.7 186 11 + + + + Mod  NPDR Mod NPDR + + - CD, FL, NFAZ CD, FL, NFAZ F 6/24 6/36 I/O
47 Gnanavelu 61 M 6 6/24 6/18 6/24 6/12 + 140/90 196 173 44 91 43 1.9 162 10.2 + + - - Mod  NPDR Mod NPDR - - - BF,NFAZ BF,NFAZ - 6/24 6/24 I/O
48 Arumugam 75 M 11 6/36 5/60 6/36 6/60 - 150/90 147 163 43 76 46 2.8 77 9.0 + + - - Mod  NPDR Sev NPDR - - - CD,BF,NFAZ CD,BF,NFAZ - 6/36 6/60 O
49 Selvambal 58 F 2 6/24 6/24 6/18 6/18 + 172/90 218 140 42 81 28 0.8 95 7.3 + - - - Mild NPDR Mild NPDR - - - CD,NFAZ, BF CD,NFAZ - 6/18 6/18 O
50 Brahmagiri 53 M 15 6/36 6/18 6/18 6/12 + 150/100 158 125 48 87 26 0.8 130 10.1 + - - - Mod  NPDR Mod NPDR - - - CD,BF.NFAZ CD,BF,NFAZ - 6/18 6/12 O
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51 Ponnusamy 44 M 7 6/36 6/24 6/36 6/24 - 120/80 286 160 36 95 28 0.9 146 7 - - - - Mild NPDR Mild NPDR - - - CD,NFAZ, BF CD,NFAZ - 6/36 6/24 O
52 Muthusamy 55 M 14 6/60 6/24 6/60 6/24 - 140/80 216 158 40 127 58 3.6 141 7 + + - - Mod  NPDR Mod NPDR + - - CD,FL,NFAZ CD,BF,NFAZ F 6/60 6/24 O
53 Venkatachalam 74 M 12 6/36 6/60 6/36 6/60 - 170/100 233 173 32 154 30 1.0 175 8.6 + - - - Sev NPDR Sev NPDR - - - CD,NFAZ, BF CD,BF,NFAZ - 6/36 6/60 O
54 Mani 60 M 11 5/60 6/60 6/36 6/60 + 180/100 281 159 38 187 28 0.8 186 10.6 + - - - NH PDR HR PDR - - VH CD,BF,NFAZ CD, BF PRP 6/36 6/60 I/O
55 Panikar 55 M 6.5 6/24 6/18 6/24 6/18 + 140/70 190 141 40 110 26 0.9 141 7.4 - - - - Mod  NPDR Mod NPDR - - - BF,NFAZ BF,NFAZ - 6/24 6/18 O
56 Kaliammal 55 F 20 6/60 6/24 4/60 4/60 + 160/90 287 145 38 96 24 1.0 25 9 + - - - NH PDR HR PDR - - VH LNV,BF,NFAZ LNV,BF,NFAZ PRP 4/60 4/60 I/O
57 Murugan 44 M 9 6/36 6/60 6/36 6/60 + 140/86 252 196 38 135 36 0.8 132 11.2 - - - - Mod  NPDR NH PDR - - - CD,NFAZ CD,LNV,BF PRP 6/36 6/60 I
58 Padmavathy 46 F 7 6/6 6/36 6/6 6/24 - 154/90 234 127 50 108 28 0.9 120 7.2 + - - - Mod  NPDR Mod NPDR - - - CD,BF,NFAZ CD,BF,NFAZ - 6/6 6/24 O
59 Mohammed Kasim 52 M 5 6/9 6/9 6/9 6/9 - 140/100 117 132 48 96 46 2.8 93 6.9 + + + - Mod  NPDR Mod NPDR - - - BF,NFAZ BF,NFAZ - 6/9 6/9 O
60 Abdul Khadar 61 M 1 6/60 5/60 6/60 5/60 - 150/90 288 199 32 124 30 1.0 149 7 + - - - Mod  NPDR Mod NPDR + + - CD,FL,NFAZ CD, FL, NFAZ F 6/24 6/36 O
61 Narayanasamy 53 M 10 3/60 6/24 3/60 6/18 + 152/100 267 158 34 116 30 0.8 167 10.1 + - + - VS NPDR Mod NPDR + - - CD, DL, BF CD,DL,NFAZ PRP, G 3/60 6/18 O
62 Basheer Ahamed 56 M 20 6/18 6/60 6/18 6/36 + 180/100 294 158 30 123 62 4.3 183 8.7 + + + + Sev NPDR VS NPDR - - - CD,BF,NFAZ CD,BF,NFAZ PRP 6/18 6/24 O
63 Shanthi 45 F 14 1/2/60 6/24 1/2/60 6/24 + 160/110 353 170 40 149 28 1.0 98 11 + - - - HR PDR VS NPDR - - VH LNV,NFAZ,BF BF,NFAZ - 1/2/60 6/24 I
64 Rathi 58 F 5 6/36 6/9 6/12 6/9 - 126/17 196 143 51 96 30 0.9 121 7 - - - - Mild NPDR Mild NPDR - - - CD,NFAZ CD,NFAZ - 6/12 6/9 O
65 Natarajan 47 M 8 6/18 6/12 6/18 6/12 - 130/80 178 158 46 183 28 0.9 147 7.5 - - - - Mod  NPDR Mod NPDR - - - CD,BF.NFAZ CD,BF,NFAZ - 6/18 6/12 O
66 Chandra 69 F 17 HM 6/12 HM 6/12 + 170/100 273 182 39 141 26 0.8 219 10 + - - - HR PDR Sev NPDR - - - LNV,BF,NFAZ CD,BF,NFAZ PRP HM 6/12 I/O
67 Ameer Basha 60 M 14 6/24 6/24 6/24 6/24 - 160/110 336 215 35 168 47 3.5 196 10.3 + + - - NH PDR NH PDR - - - CD, BF, NFAZ CD, BF, NFAZ PRP 6/12 6/12 I/O
68 Dhakshnamoorthy 44 M 9 1/60 6/60 1/60 6/36 + 140/86 248 193 41 91 28 0.8 174 9.6 - - - - HR PDR VS NPDR - - VH LNV,BF,NFAZ CD,BF,NFAZ - 1/60 6/36 I
69 Arokiamoorthy 54 M 12 6/36 6/18 6/36 6/12 - 130/86 261 168 43 162 30 0.9 153 9.7 - - - - Sev NPDR Sev NPDR - - - BF,NFAZ BF,NFAZ - 6/18 6/12 O
70 Subramanian 65 M 11 6/60 6/60 6/12 6/60 - 150/90 259 158 40 112 28 0.8 138 9 + - - - Mod  NPDR Mod NPDR - + - CD, NFAZ CD,FL,NFAZ F 6/12 6/24 O
71 Sivasubramaniam 57 M 13 6/60 6/60 6/24 6/60 - 140/80 196 141 47 118 28 0.9 120 7.6 - - - - Mod  NPDR Sev NPDR - + - CD,NFAZ, BF CD, DL, NFAZ PRP, G 6/24 6/36 O
72 Karthikeyan 56 M 11 3/60 2/60 3/60 2/60 - 160/110 318 162 35 172 48 3.3 116 11.5 + + - - HR PDR HR PDR + + - CD,FL,BF CD,FL,BF PRP, F 6/60 6/36 I/O
73 Divakaran 76 M 7 6/60 6/18 6/18 6/18 + 130/76 213 153 41 87 26 0.8 132 9 - - - - Mod  NPDR Sev NPDR - - - BF,NFAZ BF,NFAZ - 6/18 6/18 O
74 Subbulakshmi 70 F 5 6/36 6/24 6/36 6/24 - 140/90 146 98 42 91 30 1.2 99 7 + - - - Mild NPDR Mild NPDR - - - CD,NFAZ CD,NFAZ - 6/36 6/24 O
75 Nagammal 62 F 20 6/36 4/60 6/36 1/60 - 120/80 298 170 40 168 28 0.8 164 9.2 - - - - HR PDR HR PDR - - VH LNV,BF LNV,BF PRP 6/36 1/60 I
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76 Eswaramoorthy 59 M 12 6/60 6/36 6/24 6/36 + 140/90 276 151 49 155 28 0.9 158 12 + - - - Sev NPDR Sev NPDR - - - CD,BF,NFAZ CD,BF,NFAZ - 6/24 6/36 O
77 Parvathy 58 F 15 1/60 1/60 1/60 1/60 + 150/100 178 252 39 183 26 1.0 159 8.2 + - + - Mod  NPDR NH PDR - + - CD, NFAZ, BF CD, DL, NFAZ PRP, G 6/36 6/60 I/O
78 Anthony 65 M 7 6/18 6/24 6/18 6/18 - 140/84 217 153 41 88 30 0.8 150 10.2 - - - - Mod  NPDR Mod NPDR - - - BF,NFAZ BF,NFAZ - 6/18 6/18 O
79 Ganesh 44 M 1 6/6 6/18 6/6 6/6 - 110/80 195 136 39 121 30 0.9 110 7.8 - - - - Mild NPDR Mild NPDR - - - CD,NFAZ CD,NFAZ - 6/6 6/6 O
80 Krishnaveni 36 F 1.5 6/9 6/12 6/9 6/12 - 130/86 186 143 47 96 28 1.0 121 6.1 - - - - Mod  NPDR Mod NPDR - - - BF,NFAZ BF,NFAZ - 6/9 6/12 O
81 Muthulakshmi 68 F 16 6/36 1/60 6/36 1/60 - 130/74 187 147 46 101 28 0.8 106 5.6 - - - - Mod  NPDR Mod NPDR + + - CD,DL,CSME CD,DL,CSME G 6/36 6/60 O
82 Angammal 60 F 17 6/60 6/9 6/60 6/9 - 150/100 281 154 39 126 38 0.8 171 11.7 + - - - VS NPDR Mod NPDR + - BRVO DL, BF, CD CD,BF,NFAZ PRP, G 6/36 6/9 O
83 Aynush 53 F 2 6/60 6/60 6/24 6/24 - 130/70 198 124 41 87 32 0.9 139 6 - - - - Mild NPDR Mild NPDR - - - CD,NFAZ CD,NFAZ - 6/24 6/24 O
84 Murugesan 58 M 12 6/24 6/24 6/24 6/24 + 160/90 215 177 43 135 56 4.2 183 8 + + - - Sev NPDR Sev NPDR - - - BF,NFAZ BF,NFAZ - 6/24 6/24 I/O
85 Jayaseeli 55 F 17 4/60 4/60 4/60 4/60 - 160/108 243 261 48 147 30 0.8 219 12.6 + - - - Mod  NPDR HR PDR + + - CD, ISCH CD, ISCH PRP 2/60 2/60 I
86 Arokiasamy 58 M 12 6/36 6/36 6/18 6/18 - 130/80 190 156 40 108 29 1.1 183 9 - - - - Mod  NPDR Mod NPDR - - - CD,BF D,BF - 6/18 6/18 O
87 Kumarappan 67 M 25 6/60 5/60 6/60 5/60 - 170/90 244 238 36 134 49 3.7 156 8.5 + + - - Sev NPDR Sev NPDR + + - BF,DL,NFAZ BF,DL, NFAZ G 6/60 5/60 O
88 Vengaiyan 72 M 2 6/60 6/60 6/60 6/60 - 110/70 186 132 47 81 28 0.7 131 5.3 - - - - Mild NPDR Mild NPDR - - - CD,NFAZ CD,NFAZ - 6/60 6/60 O
89 Malaiammal 63 F 6 6/18 6/36 6/18 6/36 - 110/70 201 147 39 122 26 0.8 79 8.1 - - - - Mod  NPDR Mod NPDR - - - CD,BF,NFAZ CD,BF,NFAZ - 6/18 6/36 O
90 Chidambaram 52 M 10 6/12 6/18 6/12 6/18 - 160/100 158 93 47 143 32 1.7 85 9.8 + + - - NH PDR NH PDR - - - LNV,BF,NFAZ LNV,BF,NFAZ PRP 6/12 6/18 I/O
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